US20150272737A1 - Transcatheter mitral valve stent frames - Google Patents
Transcatheter mitral valve stent frames Download PDFInfo
- Publication number
- US20150272737A1 US20150272737A1 US14/662,464 US201514662464A US2015272737A1 US 20150272737 A1 US20150272737 A1 US 20150272737A1 US 201514662464 A US201514662464 A US 201514662464A US 2015272737 A1 US2015272737 A1 US 2015272737A1
- Authority
- US
- United States
- Prior art keywords
- stent
- expanded condition
- prosthetic heart
- heart valve
- valve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2409—Support rings therefor, e.g. for connecting valves to tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
- A61F2/2445—Annuloplasty rings in direct contact with the valve annulus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0065—Three-dimensional shapes toroidal, e.g. ring-shaped, doughnut-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
Definitions
- the present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to designs for stent frames for collapsible prosthetic heart valves.
- Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible.
- a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.
- Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent.
- a stent There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent.
- the valve is generally first collapsed or crimped to reduce its circumferential size.
- the prosthetic valve When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size.
- this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent.
- the stent automatically expands as the sheath covering the valve is withdrawn.
- a prosthetic heart valve may include a stent having an inflow end, an outflow end, a center portion between the inflow end and the outflow end, a collapsed condition, and an expanded condition.
- a collapsible and expandable valve assembly may be disposed within the stent and may have a plurality of leaflets.
- a first annular sealing member may be coupled to the inflow end and a second annular sealing member may be coupled to the outflow end.
- a stent having an expanded condition and a collapsed condition may include a substantially cylindrical body having a first end and a second end.
- a flared portion may be coupled to the first end of the body and may extend radially outwardly from the body and away from the second end of the body when the stent is in the expanded condition.
- a plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition.
- the flared portion and the second free ends of the anchor members may be configured to extend away from the second end of the body when the stent is in the collapsed condition.
- a stent having an expanded condition and a collapsed condition may include a substantially cylindrical center body having a first end and a second end.
- a first plurality of anchor members may each have a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition.
- a second plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition.
- the first and second plurality of anchor members may be configured to extend toward the second end of the body when the stent is in the collapsed condition.
- a stent having an expanded condition and a collapsed condition may include a substantially cylindrical center body having a first end and a second end.
- a first plurality of anchor members each having a first end coupled to the body and a second free end may extend radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition.
- a second plurality of anchor members each having a first end coupled to the first end of the body and a second free end may extend radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition.
- the first plurality of anchor members may extend toward the first end of the body and the second plurality of anchor members may extend toward the second end of the body when the stent is in the collapsed condition.
- a stent having an expanded condition and a collapsed condition may include a substantially cylindrical center body having a first end, a second end, and a longitudinal axis extending between the first end and the second end.
- a first plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition.
- a second plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition.
- the first plurality of anchor members may extend away from the second end of the body and the second plurality of anchor members may extend away from the first end of the body when the stent is in the collapsed condition.
- a prosthetic heart valve may include a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition.
- the stent may be formed from wire and may have a first series of hooks and a second series hooks.
- a cuff may be coupled to the stent.
- a prosthetic heart valve may include a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition.
- the stent may be formed of a plurality of struts.
- a collapsible and expandable valve assembly may be disposed within the stent and may have a plurality of leaflets.
- a commissure attachment feature may be attached to at least one of the plurality of struts and may be positioned between the inflow end and the outflow end when the stent is in the expanded condition.
- FIG. 1 is a schematic cutaway representation of a human heart showing a transapical delivery approach
- FIG. 2 is a schematic representation of a native mitral valve and associated cardiac structures
- FIG. 3A is a side view of a prosthetic heart valve according to the prior art
- FIG. 3B is a longitudinal cross-section of the prosthetic heart valve of FIG. 3A ;
- FIG. 4A is a schematic perspective view of a prosthetic heart valve according to the present disclosure.
- FIG. 4B is a longitudinal cross-section of the prosthetic heart valve of FIG. 4A ;
- FIG. 4C is a schematic representation of the prosthetic heart valve of FIG. 4A disposed in a native valve annulus;
- FIG. 5A is a schematic cut-away perspective view of another prosthetic heart valve according to the present disclosure.
- FIG. 5B is a longitudinal cross-section of the prosthetic heart valve of FIG. 5A ;
- FIG. 5C is a schematic representation of the prosthetic heart valve of FIG. 5A disposed in a native valve annulus;
- FIG. 6A is a schematic perspective view of a docking station for use with a prosthetic heart valve
- FIG. 6B is a cross-sectional view of the docking station of FIG. 6A ;
- FIG. 6C is a schematic representation of the docking station of FIG. 6A disposed in a native valve annulus with a prosthetic heart valve disposed within the docking station.
- FIG. 7A is a perspective view of a stent of a prosthetic heart valve according to the present disclosure.
- FIG. 7B is a schematic representation of the stent of FIG. 7A disposed in a native valve annulus
- FIG. 7C is a perspective view of another stent of a prosthetic heart valve according to the present disclosure.
- FIG. 7D is a schematic representation of the stent of FIG. 7C disposed in a native valve annulus
- FIG. 8A is a side view of another stent of a prosthetic heart valve according to the present disclosure.
- FIG. 8B is a schematic representation of the stent of FIG. 8A disposed in a native valve annulus
- FIG. 9 is a developed view of a further stent of a prosthetic heart valve according to the present disclosure.
- FIG. 10 is a perspective view of yet another stent of a prosthetic heart valve according to the present disclosure.
- FIG. 11 is a perspective view of another prosthetic heart valve according to the present disclosure.
- FIG. 12 is a side view of a further prosthetic heart valve according to the present disclosure.
- FIG. 13 is a perspective view of still another stent of a prosthetic heart valve according to the present disclosure.
- the term “inflow end,” when used in connection with a prosthetic mitral heart valve, refers to the end of the heart valve closest to the left atrium when the heart valve is implanted in a patient
- the term “outflow end,” when used in connection with a prosthetic mitral heart valve refers to the end of the heart valve closest to the left ventricle when the heart valve is implanted in a patient.
- proximal and distal are to be taken as relative to a user using the device in an intended manner.
- Proximal is to be understood as relatively close to the user and “distal” is to be understood as relatively farther away from the user.
- distal is to be understood as relatively farther away from the user.
- the terms “substantially,” “generally,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified.
- materials described as being suitable for components in one embodiment may also be suitable for similar components described in other embodiments.
- FIG. 1 is a schematic cutaway representation of human heart 100 .
- the human heart includes two atria and two ventricles: right atrium 112 and left atrium 122 , and right ventricle 114 and left ventricle 124 .
- Heart 100 further includes aorta 110 , and aortic arch 120 .
- mitral valve 130 Disposed between the left atrium and the left ventricle is mitral valve 130 .
- Mitral valve 130 also known as the bicuspid valve or left atrioventricular valve, is a dual-flap that opens as a result of increased pressure in left atrium 122 as it fills with blood. As atrial pressure increases above that of left ventricle 124 , mitral valve 130 opens and blood passes into left ventricle 124 . Blood flows through heart 100 in the direction shown by arrows “B”.
- a dashed arrow, labeled “TA”, indicates a transapical approach of implanting a prosthetic heart valve, in this case to replace the mitral valve.
- TA transapical approach of implanting a prosthetic heart valve
- TS transseptal approach of implanting a prosthetic heart valve in which the valve is passed through the septum between right atrium 112 and left atrium 122 .
- Other approaches for implanting a prosthetic heart valve are also possible.
- FIG. 2 is a more detailed schematic representation of native mitral valve 130 and its associated structures.
- mitral valve 130 includes two flaps or leaflets, posterior leaflet 136 and anterior leaflet 138 , disposed between left atrium 122 and left ventricle 124 .
- Cord-like tendons known as chordae tendineae 134 , connect the two leaflets 136 , 138 to the medial and lateral papillary muscles 132 .
- chordae tendineae 134 connect the two leaflets 136 , 138 to the medial and lateral papillary muscles 132 .
- blood flows from higher pressure in left atrium 122 to lower pressure in left ventricle 124 .
- leaflets 136 , 138 When left ventricle 124 contracts in ventricular systole, the increased blood pressure in the chamber pushes leaflets 136 , 138 to close, preventing the backflow of blood into left atrium 122 . Since the blood pressure in left atrium 122 is much lower than that in left ventricle 124 , leaflets 136 , 138 attempt to evert to the low pressure regions. Chordae tendineae 134 prevent the eversion by becoming tense, thus pulling on leaflets 136 , 138 and holding them in the closed position.
- FIGS. 3A and 3B are a side view and a longitudinal cross-sectional view of prosthetic heart valve 300 according to the prior art.
- Prosthetic heart valve 300 is a collapsible prosthetic heart valve designed to replace the function of the native mitral valve of a patient (see native mitral valve 130 of FIGS. 1-2 ).
- prosthetic valve 300 has a substantially cylindrical shape with inflow end 310 and outflow end 312 .
- prosthetic valve 300 may have a low profile so as not to interfere with atrial function in the native valve annulus.
- Prosthetic heart valve 300 may include stent 350 , which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.
- Stent 350 may include a plurality of struts 352 that form cells 354 connected to one another in one or more annular rows around the stent. Cells 354 may all be of substantially the same size around the perimeter and along the length of stent 350 . Alternatively, cells 354 near inflow end 310 may be larger than the cells near outflow end 312 .
- Stent 350 may be expandable to provide a radial force to assist with positioning and stabilizing prosthetic heart valve 300 in the native valve annulus.
- Prosthetic heart valve 300 may also include a substantially cylindrical valve assembly 360 including a pair of leaflets 362 ( FIG. 3B ) attached to a cuff 364 ( FIG. 3A ).
- Leaflets 362 replace the function of native mitral valve leaflets 136 and 138 described above with reference to FIG. 2 . That is, leaflets 362 coapt with one another to function as a one-way valve.
- prosthetic heart valve 300 is illustrated as having a valve assembly 360 with two leaflets 362 , it will be appreciated that prosthetic heart valve 300 may have more than two leaflets when used to replace the mitral valve or other cardiac valves within a patient.
- Both cuff 364 and leaflets 362 may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or polymers, such as polytetrafluoroethylene (PTFE), urethanes and the like.
- Valve assembly 360 may be secured to stent 350 by suturing to struts 352 or by using tissue glue, ultrasonic welding or other suitable methods.
- prosthetic heart valve 300 When prosthetic heart valve 300 is implanted in a patient, for example at the annulus of native mitral valve 130 , it is biased towards an expanded condition, providing radial force to anchor the valve in place. However, if the radial force is too high, damage may occur to heart tissue. If, instead, the radial force is too low, the heart valve may move from its implanted position, for example, into either left ventricle 124 or left atrium 122 , requiring emergency surgery to remove the displaced valve. The potential for such movement may be heightened in mitral valve applications, particularly if a low profile valve is used.
- prosthetic heart valves Another potential issue with prosthetic heart valves is inadequate sealing between the prosthetic valve and the native tissue. For example, if prosthetic heart valve 300 is implanted at the annulus of mitral valve 130 in a patient, improper or inadequate sealing may result in blood flowing from left ventricle 124 into left atrium 122 , even if leaflets 362 of valve assembly 360 are working properly. This may occur, for example, if blood flows in a retrograde fashion between the outer perimeter of prosthetic heart valve 300 and the native tissue at the site of implantation. This phenomenon is known as perivalvular (or paravalvular) leak (“PV leak”).
- PV leak perivalvular (or paravalvular) leak
- FIGS. 4A and 4B illustrate a prosthetic heart valve 400 according to one embodiment of the disclosure in perspective and longitudinal cross-section views, respectively.
- Prosthetic heart valve 400 is a collapsible prosthetic heart valve designed to replace the function of the native mitral valve of a patient.
- prosthetic valve 400 has inflow end 410 and outflow end 412 .
- Prosthetic heart valve 400 may include stent 450 , which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.
- Stent 450 may include a plurality of struts 452 that form cells 454 connected to one another in one or more annular rows around the stent.
- Stent 450 may be radially expandable to provide a radial force to assist with positioning and stabilizing prosthetic heart valve 400 in the native mitral valve annulus.
- Stent 450 may be substantially cylindrically shaped when in the expanded condition.
- Prosthetic heart valve 400 may also include valve assembly 460 including a pair of leaflets 462 .
- Leaflets 462 function similarly to leaflets 362 described above in connection with FIG. 3B , and more or fewer leaflets may be used in other applications.
- prosthetic heart valve 400 may include a first sealing ring 480 positioned at inflow end 410 and a second sealing ring 490 positioned at outflow end 412 .
- Each sealing ring 480 , 490 may be formed of a biocompatible material that allows tissue ingrowth.
- sealing rings 480 and 490 may be formed of fabrics and/or polymers, such as polytetrafluoroethylene (PTFE), urethanes and the like.
- sealing rings 480 and 490 may be formed of traditional stent materials, such as shape memory alloys including Nitinol, and may take forms including Nitinol coils.
- sealing rings 480 and 490 may be formed from a metal or polymer mesh or braid. Still further, sealing rings 480 , 490 may be formed of tissue, such as porcine cardiac tissue. Some or all of the above materials may be used in combination with a coating, such as a collagen coating, a fibrin coating, or a polymer coating (such as a silicone coating). Sealing rings 480 and 490 may be attached to inflow end 410 and outflow end 412 , respectively, by, for example, sutures, adhesives, ultrasonic welding or other suitable methods. Alternatively, if sealing rings 480 and 490 are formed of the same material as stent 450 , sealing rings 480 and 490 may be formed integrally with stent 450 .
- Each sealing ring 480 , 490 is generally annular, with a center portion of each sealing ring being attached to stent 450 so that blood may flow through the stent.
- Sealing rings 480 and 490 may each have an outer diameter that is greater than the diameter of stent 450 when in the expanded condition.
- sealing rings 480 and 490 each have a substantially planar configuration. However, other shapes and sizes may be suitable depending on the particular anatomy of the patient.
- FIG. 4C shows prosthetic heart valve 400 implanted within native valve annulus VA between left atrium 122 and left ventricle 124 .
- first sealing ring 480 is positioned on the atrial side of native valve annulus VA while second sealing ring 490 is positioned on the ventricular side of native valve annulus VA.
- Sealing rings 480 and 490 may help prevent PV leak by preventing blood from flowing from left ventricle 124 to left atrium 122 between the native valve annulus VA and the outer perimeter of prosthetic heart valve 400 . This function may be enhanced once tissue begins to grow into first sealing ring 480 and second sealing ring 490 .
- sealing ring 480 may provide an anchoring effect, helping to prevent prosthetic heart valve 400 from migrating toward left ventricle 124 .
- second sealing ring 490 may also provide an anchoring effect, helping to prevent prosthetic heart valve 400 from migrating toward left atrium 122 .
- This additional anchoring ability may reduce the radial force required of stent 450 to keep prosthetic heart valve 400 secured in native valve annulus VA, which, in turn, may allow stent 450 to have a smaller fully expanded diameter than traditional stents.
- This reduction in size may be possible, in part, due to a reduction or elimination of the need to have a relatively large stent frame to maximize the range of anatomies which could accept the stent and still have enough radial force to hold the stent in place.
- the relatively smaller diameter which may be possible due to the above-described features may result in lower hydrodynamic load on prosthetic heart valve 400 , which may reduce the stresses on valve assembly 460 and which also may reduce the strain on the material forming stent 450 .
- FIGS. 5A and 5B illustrate a prosthetic heart valve 500 according to another embodiment of the disclosure.
- Prosthetic heart valve 500 is similar to prosthetic heart valve 400 in certain respects.
- prosthetic heart valve 500 may include stent 550 , which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.
- Stent 550 may include a plurality of struts 552 that form cells 554 connected to one another in one or more annular rows around the stent.
- Stent 550 may be radially expandable to provide a radial force to assist with positioning and stabilizing prosthetic heart valve 500 in the native valve annulus.
- Stent 550 has the general shape of a cylinder, except that it is bowed inwardly from inflow end 510 and outflow end 512 toward the center. In other words, stent 550 has a concave shape, wherein the center of stent 550 has a smaller diameter than that of inflow end 510 and outflow end 512 when in the expanded condition.
- Prosthetic heart valve 500 may also include valve assembly 560 including a pair of leaflets 562 .
- Leaflets 562 function similarly to leaflets 362 described above in connection with FIG. 3B , and more or fewer leaflets may be used in other applications.
- Prosthetic heart valve 500 may also include a number of sealing elements.
- prosthetic heart valve 500 may include a first sealing ring 580 positioned at inflow end 510 and a second sealing ring 590 positioned at outflow end 512 .
- Sealing rings 580 , 590 may be generally similar to sealing rings 480 , 490 , with the exception that first sealing ring 580 is curved toward outflow end 512 and second sealing ring 590 is curved toward inflow end 510 .
- sealing rings 580 and 590 are substantially non-planar when stent 550 is in the expanded condition.
- Sealing rings 580 , 590 may be formed of the same biocompatible materials described above for forming sealing rings 480 and 490 , and may be attached to inflow end 510 and outflow end 512 , respectively, in the same manner as sealing rings 480 and 490 .
- Each sealing ring 580 , 590 is generally annular, with a center portion of each sealing ring being attached to stent 550 so that blood may flow through the stent.
- sealing rings 580 , 590 may be curved away from the ends of stent 550 to which the rings are attached. In other words, the outer perimeter of first sealing ring 580 is closer to outflow end 512 than the inner perimeter of that sealing ring. Similarly, the outer perimeter of second sealing ring 590 is closer to inflow end 510 than the inner perimeter of that sealing ring.
- other shapes and sizes may be suitable depending on the particular anatomy of the patient.
- FIG. 5C shows prosthetic heart valve 500 implanted within native valve annulus VA between left atrium 122 and left ventricle 124 .
- first sealing ring 580 is positioned on the atrial side of native valve annulus VA while second sealing ring 590 is positioned on the ventricular side of native valve annulus VA.
- sealing rings 580 and 590 mitigate PV leak by preventing blood from flowing from left ventricle 124 to left atrium 122 between the native valve annulus VA and the outer perimeter of prosthetic heart valve 500 .
- tissue begins to grow into first sealing ring 580 and second sealing ring 590 , PV leak may be mitigated to an even greater extent.
- first sealing ring 580 may provide an anchoring effect, helping to prevent prosthetic heart valve 500 from migrating toward left ventricle 124 .
- second sealing ring 590 may also provide an anchoring effect, helping to prevent prosthetic heart valve 500 from migrating toward left atrium 122 .
- the curvature of sealing rings 580 and 590 may dictate, in part, how prosthetic heart valve 500 interacts with the anatomy and how stresses are distributed in valve 500 .
- the above-described curvature may have an enhanced effect on sealing and anchoring in comparison to a relatively flat or planar sealing ring. This may be due, in part, to the anatomy near the implant site having generally non-planar surfaces.
- sealing rings 580 and 590 may effectively pinch tissue of the annulus resulting in enhanced sealing and anchoring, while also increasing apposition to the annulus by forcing any irregular anatomic geometries into the pinched area.
- the inwardly bowed shape of stent 550 may provide a greater contact area between stent 550 and the native valve annulus VA.
- FIGS. 6A and 6B illustrate a prosthetic heart valve docking station 600 according to one embodiment of the disclosure in perspective and longitudinal cross-sectional views, respectively.
- docking station 600 may first be implanted in a native valve annulus, and a prosthetic heart valve may be subsequently implanted in docking station 600 .
- Docking station 600 has inflow end 610 and outflow end 612 , and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Docking station 600 may alternatively be made of a material that is not self-expandable, such as stainless steel, which may be expanded with the use of a separate expandable structure, such as a balloon.
- Docking station 600 may have the general form of a hollow tube with a cylindrical center section 670 and anchoring members extending radially outwardly at inflow end 610 and outflow end 612 .
- the illustrated embodiment of docking station 600 includes first anchor rim 680 and second anchor rim 690 .
- the particular shape of each anchor rim 680 , 690 may be varied.
- first anchor rim 680 may have a cylindrical outer surface 682 that is substantially concentric to cylindrical center section 670 .
- One end surface 684 of anchor rim 680 coextensive with inflow end 610 may lie in a plane perpendicular to the axis of rotation of central section 670 .
- Second anchor rim 690 may have a similar structure. That is, second anchor rim 690 may have a cylindrical outer surface 692 that is substantially concentric to center section 670 .
- One end surface 694 of anchor rim 690 coextensive with outflow end 612 may lie in a plane perpendicular to the axis of rotation of center section 670 , while the other end surface 696 of anchor rim 690 may be inclined at an oblique angle to that axis of rotation.
- the inclined surfaces of anchor rims 680 and 690 may provide better contact with a native valve annulus, but may be varied and still be within the scope of this disclosure.
- FIG. 6C shows docking station 600 implanted within native valve annulus VA between left atrium 122 and left ventricle 124 .
- first anchor rim 680 is positioned on the atrial side of native valve annulus VA while anchor rim 690 is positioned on the ventricular side of native valve annulus VA.
- Anchor rims 680 and 690 may provide an anchoring effect, helping prevent docking station 600 from migrating toward left ventricle 124 or left atrium 122 .
- prosthetic heart valve PHV may be assembled to the docking station.
- a number of benefits may result from using a two-step process in which docking station 600 is first implanted within native valve annulus VA and then prosthetic heart valve PHV is assembled to docking station 600 .
- prosthetic heart valve PHV which may take the form of any traditional prosthetic heart valve or any of the embodiments disclosed herein, will encounter a predictable environment. That is, the variability in anatomy from one patient to another will have less effect on the positioning and functioning of prosthetic heart valve PHV, because prosthetic heart valve PHV will interact directly with docking station 600 rather than with the anatomy of native valve annulus VA.
- FIG. 7A illustrates a stent 700 of a prosthetic heart valve according to one embodiment of the disclosure.
- Stent 700 is collapsible and expandable for use in a prosthetic heart valve intended to replace the function of the native mitral valve of a patient.
- stent 700 is illustrated in its expanded condition.
- the remaining components that would be attached to stent 700 to form a prosthetic heart valve, such as leaflets and a cuff, are omitted from the figures for clarity.
- Stent 700 has inflow end 710 and outflow end 712 , and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Stent 700 may include a plurality of struts 752 that form cells connected to one another in one or more annular rows around the stent.
- Stent 700 may be thought of as having at least three main portions. At inflow end 710 is flared portion 770 , which flares radially outwardly in a direction away from outflow end 712 . Flared portion 770 may include one or more circumferential rows of relatively small cells 754 a . Each cell 754 a is formed from a group of struts 752 that defines a geometric shape having a relatively small area, in this case generally a diamond shape.
- Stent 700 also includes a substantially cylindrical body 780 that extends from flared portion 770 to outflow end 712 of the stent.
- Body 780 may include one or more circumferential rows of relatively large cells 754 b .
- Each cell 754 b is formed from a group of struts 752 that defines a geometric shape having a relatively large area, in this case generally a diamond shape.
- Struts 752 forming larger cells 754 b may be thicker and stronger than struts 752 forming smaller cells 754 a .
- Rows of relatively small cells 754 a may be thought of as being a high-density arrangement of cells, while rows of relatively large cells 754 b may be thought as being a low-density arrangement of cells.
- Stent 700 also includes a portion with anchor members, in this case hooks 790 .
- Hooks 790 are formed of struts 752 that extend radially outwardly toward inflow end 710 . Hooks 790 may be integral with stent 700 , being formed from the same single piece of starting material, and may be connected to stent 700 anywhere on body 780 . It should be noted that the term hooks may include other anchoring structures, for example barbs or clips.
- stent 700 When being used in a prosthetic heart valve for replacing the native mitral valve of a patient, stent 700 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device.
- the delivery device may, for example, be inserted through the apex of the heart (transapical delivery) or through the femoral artery and passed through the vasculature to the implant site (transfemoral delivery). Once the delivery device is near the site of implantation, the sheath or other member compressing stent 700 may be slowly retracted to reveal stent 700 and allow it to expand to the expanded condition.
- hooks 790 are first released from the proximal portion of the sheath and expand.
- the release of hooks 790 may be performed in left ventricle 124 and then pushed distally until hooks 790 catch native leaflets 136 and 138 .
- the release of hooks 790 may be performed in left atrium 122 , then pulled proximally into left ventricle 124 and then pushed back to catch native leaflets 136 and 138 .
- hooks 790 may be accomplished with other types of sheaths, for example with a double proximal sheath with a slot or other opening in the inner sheath to allow hooks 790 to deploy first. It should be noted that in the collapsed condition, hooks 790 point toward inflow end 710 , rather than toward outflow end 712 . In other words, hooks 790 (as well as flared portion 770 ) are folded toward left atrium 122 during deployment, such that hooks 790 may gradually expand outwardly as the delivery sheath is slowly retracted. If, on the other hand, hooks 790 were delivered folded toward left ventricle 124 , once the delivery sheath cleared hooks 790 , the hooks would suddenly flip nearly 180 degrees, possibly causing trauma to native valve annulus VA.
- flared portion 770 begins to expand on the atrial side of the native valve annulus VA.
- Prosthetic heart valve 700 is illustrated after full release in FIG. 7B .
- the inclusion of smaller cells 754 a in a high-density arrangement in flared portion 770 allows for relatively greater tissue ingrowth and also facilitates creating and maintaining the flared shape of flared portion 770 , which provides for better alignment and sealing at inflow end 710 of stent 700 .
- body 780 and hooks 790 hook around the native anterior and posterior mitral valve leaflets, helping secure stent 700 in place.
- body 780 is generally comprised of larger cells 754 b formed of thicker struts 752 instead of smaller cells 754 a formed of thinner struts, body 780 is somewhat more rigid and facilitates better anchoring by hooks 790 . This better anchoring may be partly due to the fact that hooks 790 are connected to body 780 , and may also be formed of relatively thick struts 752 to provide additional strength.
- stent 700 may be resheathed any time prior to release of flared portion 770 into the expanded condition, for example by pushing a proximal portion of a split sheath distally before the distal portion of the split sheath is released. If a double proximal sheath were used, stent 700 could be resheathed at any time prior to release of the entire stent into the expanded condition.
- stent 700 may include one or more commissure attachment features (“CAFs”) 792 and one or more retention members 794 as are known in the art.
- Each CAF 792 provides a site for the prosthetic valve leaflets to be attached to stent 700 .
- Each retention member 794 provides a feature for connecting stent 700 to the delivery device, the connection being maintained until stent 700 is fully released from the delivery device.
- hooks 790 are shown as being formed integrally with stent 700 , hooks 790 may be formed separately of any one or a combination of a variety of materials, including for example Nitinol, polymers such as polyvinyl alcohol (“PVA”), and tissues such as bovine or porcine cardiac tissue.
- PVA polyvinyl alcohol
- FIG. 7C illustrates an alternate embodiment of stent 700 ′ of a prosthetic heart valve according to another embodiment of the disclosure.
- an opaque strip of material is positioned within stent 700 ′ to more clearly demonstrate features of the stent.
- This strip of material forms no part of stent 700 ′ or the prosthetic valve incorporating the stent.
- Stent 700 ′ has features in common with stent 700 .
- stent 700 ′ is collapsible and expandable, has inflow end 710 ′ and outflow end 712 ′, and may be formed from biocompatible materials that are capable of self-expansion.
- Stent 700 ′ may include a plurality of struts 752 ′ that form cells connected to one another in one or more annular rows around the stent.
- Stent 700 ′ includes flared portion 770 ′ at inflow end 710 ′. Flared portion 770 ′ extends radially outwardly in a direction away from outflow end 712 ′ and may include one or more circumferential rows of cells 754 ′.
- Stent 700 ′ may also include a substantially cylindrical body 780 ′ that extends from outflow end 712 ′ toward inflow end 710 ′. Body 780 ′ may include one or more circumferential rows of cells 754 ′.
- Each cell 754 ′ may be formed from a group of struts 752 ′ that defines a general diamond shape.
- Stent 700 ′ may also include a portion with anchor members, such as hooks 790 ′.
- Hooks 790 ′ may be formed of struts 752 ′ that extend radially outwardly toward inflow end 710 ′, and then angle back such that they extend generally parallel to a longitudinal axis of stent 700 ′.
- Hooks 790 ′ may be integral with stent 700 ′, being formed from the same single piece of starting material, and may be connected to stent 700 ′ anywhere on body 780 ′. Hooks 790 ′ may be generally similar to hooks 790 of stent 700 , with at least two distinctions.
- hooks 790 ′ extend at a first angle and then angle back such that a free end of each hook 790 ′ is generally parallel to the longitudinal axis of stent 700 ′. As illustrated in FIG. 7D , this configuration may provide a better clamping action of native valve leaflets 136 and 138 . It should be noted that the free end of hooks 790 ′ need not be exactly parallel to the longitudinal axis and variations from parallel may exist. Second, the free end of hooks 790 ′ may be rounded or otherwise curved. Compared to a free end with a sharp angle, hooks 790 ′ may be less traumatic to the native tissue.
- Flared portion 770 ′ may also vary from flared portion 770 of stent 700 , at least in that flared portion 770 ′ is not connected to body 780 ′ at the tip of a cell 754 ′. Rather than being connected to the portion of body 780 ′ that is closest to inflow end 710 ′, flared portion 770 ′ is connected to body 780 ′ farther toward outflow end 712 ′. In the illustrated embodiment, flared portion 770 ′ is connected to body 780 ′ at a point where two adjacent cells 754 ′ in the same circumferential row meet. This configuration results in some overlap in the longitudinal direction of flared portion 770 ′ and body 780 ′. When implanted, as illustrated in FIG.
- flared portion 770 ′ makes contact with native valve annulus VA, while the points on body 780 ′ closest to inflow end 710 ′ extend a distance into left atrium 122 . Because structures including a cuff and valve assembly (not illustrated in FIGS. 7C-D ) would be attached to body 780 ′, retaining the cylindrical geometry of body 780 ′ near the point of contact between flared portion 770 ′ and native valve annulus VA may help more evenly distribute the pressures and forces exerted on stent 700 ′ during normal operation.
- the delivery and deployment of a prosthetic heart valve incorporating stent 700 ′ may be substantially the same as described above in relation to stent 700 .
- FIG. 8A illustrates a stent 800 of a prosthetic heart valve according to another embodiment of the disclosure.
- Stent 800 is collapsible and expandable for use in a prosthetic heart valve for replacing the function of the native mitral valve of a patient.
- stent 800 is illustrated in its expanded condition.
- Stent 800 has inflow end 810 and outflow end 812 , and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Stent 800 may include a plurality of struts 852 that form cells 854 connected to one another in one or more annular rows around the stent.
- Stent 800 includes a substantially cylindrical body 870 and two anchor sections.
- the anchor sections may take the form of a first circumferential row of hooks 880 and a second circumferential row of hooks 890 .
- Each hook 880 in the first circumferential row has a first end attached to inflow end 810 of stent 800 and a free end extending radially outwardly and toward outflow end 812 of stent 800 in the expanded condition.
- an opaque strip of material is positioned between first circumferential row of hooks 880 and body 870 to more clearly demonstrate their relative radial positioning.
- Each hook 890 in the second circumferential row has a first end attached to body 870 of stent 800 at a spaced distance from inflow end 810 and a free end extending radially outwardly and toward outflow end 812 in the expanded condition.
- stent 800 When being used in a prosthetic heart valve for replacing the native mitral valve of a patient, stent 800 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. In the collapsed condition, the free ends of hooks 880 in the first circumferential row and the free ends of hooks 890 in the second circumferential row all point toward outflow end 812 of stent 800 . If a transfemoral or transaortic delivery route is used, once at the site of implantation, a sheath covering stent 800 may be retracted such that outflow end 812 of stent 800 expands first.
- FIG. 8B illustrates stent 800 in its fully expanded state within native mitral valve annuls VA.
- hooks 880 in the first circumferential row are positioned on, and in contact with, the atrial side of native valve annulus VA.
- Hooks 890 in the second circumferential row are positioned on, and in contact with, the ventricular side of native valve annulus VA. This positioning facilitates anchoring of stent 800 in native valve annulus VA, and helps to prevent PV leak.
- stent 800 may be resheathed any time prior to release of the entire stent into the expanded condition.
- the transition of hooks 880 and 890 from the collapsed condition to the expanded condition is relatively gradual, decreasing the likelihood of trauma to native valve annulus VA during release of stent 800 from the sheath.
- a similar result may be achieved with a transapical delivery route if a sheath with a distal pull-off is used.
- other routes not specifically mentioned herein, such through the inferior vena cava may be used with an appropriate sheath to allow the desired order of release and resheathing capabilities, as would be understood by one of ordinary skill in the art.
- stent 800 may include one or more CAFs 892 and one or more retention members 894 as are known in the art. It should be noted that retention members 894 are on inflow end 810 in this case because inflow end 810 is intended to be released at the end of deployment. This is in contrast to retention members 794 of stent 700 in FIG. 7A , which are on outflow end 712 because outflow end 712 of stent 700 is intended to be released at the end of deployment.
- FIG. 9 illustrates stent 900 of a prosthetic heart valve according to a further embodiment of the disclosure.
- Stent 900 is collapsible and expandable for use in a prosthetic heart valve intended to replace the function of the native mitral valve of a patient.
- stent 900 is illustrated as if it were cut longitudinally and laid out in a flat, expanded condition.
- Stent 900 has inflow end 910 and outflow end 912 and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.
- Stent 900 may include a plurality of struts 952 that form cells 954 connected to one another in one or more annular rows around the stent.
- Stent 900 includes a substantially cylindrical body 970 and two anchor sections.
- the anchor sections may take the form of a first circumferential row of hooks 980 and a second circumferential row of hooks 990 .
- Each hook 980 in the first circumferential row has a first end attached to inflow end 910 of stent 900 and a free end extending radially outwardly and toward outflow end 912 of stent 900 when in the expanded condition.
- Each hook 990 in the second circumferential row has a first end attached to body 970 of stent 900 at a spaced distance from inflow end 910 and a free end extending radially outwardly and toward inflow end 910 of stent 900 when in the expanded condition.
- hooks 980 and 990 may extend generally perpendicular to stent body 970 or at an oblique angle towards either inflow end 910 or outflow end 912 . It should also be noted that each circumferential row of hooks 980 or 990 need not be continuous. For example, groups of one, two, or more hooks 990 may be provided to anchor stent 900 to native anterior and posterior mitral valve leaflets, with a number of cells 954 without hooks 990 being positioned between the groups.
- stent 900 When used in a prosthetic heart valve intended to replace the native mitral valve of a patient, stent 900 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. In the collapsed condition, the free ends of hooks 980 in the first circumferential row and the free ends of hooks 990 in the second circumferential row all point toward the center of stent 900 . This may be particularly useful when a split sheath is being used to deploy stent 900 .
- a split sheath refers to a sheath that is configured to house stent 900 in a collapsed condition and a portion of the sheath housing the stent may move distally with respect to the stent while the remainder of the sheath housing the stent may remain stationary or may independently move proximally with respect to the stent.
- inflow end 910 may be exposed before or after outflow end 912 .
- distal movement of one portion of the sheath housing will expose inflow end 910
- proximal movement of the remainder of the sheath housing will expose outflow end 912 .
- hooks 980 and 990 may be deployed in any desired order, it may be preferable to first deploy second circumferential row of hooks 990 in left ventricle 124 and then push stent 900 such that hooks 990 engage native valve leaflets 136 and 138 . Once engaged, and first circumferential row of hooks 980 may be deployed in left atrium 122 while keeping a portion of the distal delivery sheath covering inflow end 910 . Once proper positioning is verified, the distal sheath may be pushed beyond inflow end 910 and the proximal sheath may be pulled off the outflow end 912 to fully release stent 900 .
- stent 900 When in the fully expanded condition, stent 900 may be anchored to the native mitral valve in a manner similar to that illustrated in FIG. 8B . However, unlike other embodiments described herein, the configurations of hooks 980 and 990 allow the entire stent 900 to be resheathed prior to the full release of the stent when a split sheath device is used for deployment.
- FIG. 10 illustrates a stent 1000 of a prosthetic heart valve according to a further embodiment of the disclosure.
- Stent 1000 is collapsible and expandable for use in a prosthetic heart valve for replacing the function of the native mitral valve of a patient.
- stent 1000 is illustrated in the expanded condition.
- Stent 1000 has inflow end 1010 and outflow end 1012 and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.
- Stent 1000 may include a plurality of struts 1052 that form cells 1054 connected to one another in one or more annular rows around the stent.
- Stent 1000 includes a substantially cylindrical body 1070 and two anchor sections.
- the anchor sections may take the form of a first circumferential row of hooks 1080 and a second circumferential row of hooks 1090 .
- Each hook 1080 in the first circumferential row has a first end attached to inflow end 1010 of stent 1000 and a free end extending radially outwardly.
- Each hook 1090 in the second circumferential row has a first end attached to outflow end 1012 of stent 1000 and a free end extending radially outwardly.
- hooks 1080 and 1090 may extend substantially perpendicularly to the central axis of body 1070 or, for each circumferential row, the hooks in that circumferential row may extend at an angle towards the hooks in the other circumferential row.
- Each hook 1080 may be a part of a single cell 1054 that is also part of body 1070 .
- each hook 1090 may be part of a single cell 1054 that is also part of body 1070 .
- the first circumferential row of hooks 1080 may extend continuously around the perimeter of inflow end 1010 . In other words, each cell 1054 at inflow end 1010 may form a hook 1080 .
- hooks 1080 need not extend continuously around the perimeter of inflow end 1010 and cells 1054 not forming a hook may be interposed between cells that do form hooks.
- the second circumferential row of hooks 1090 is preferably not continuous.
- at least some cells 1054 at outflow end 1012 preferably do not from a hook 1090 .
- cells 1054 terminating in a CAF 1094 preferably do not form a hook 1090 , otherwise the ability to attach a prosthetic valve to stent 1000 could be hindered.
- stent 1000 When used in a prosthetic heart valve to replace the native mitral valve of a patient, stent 1000 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. In the collapsed condition, the free ends of hooks 1080 in the first circumferential row point away from outflow end 1012 and the free ends of hooks 1090 in the second circumferential row point away from inflow end 1010 .
- stent 1000 may be only partially resheathable. In other words, if the hooks in only one circumferential row have been deployed from the delivery device, stent 1000 may be resheathed to reposition its associated prosthetic valve. If, on the other hand, the hooks in both circumferential rows have been deployed from the delivery device, stent 1000 may no longer be resheathed even if retention members 1094 are still connected to the delivery device. Despite being only partially resheathable, the configuration of stent 1000 may provide a number of benefits.
- stent 1000 generally has a less complex structure than, for example, stents 700 , 800 , and 900 , which may result in simplified manufacturing. Also, at least partly because hooks 1080 and 1090 are portions of cells 1054 of body 1070 , all cells 1000 of stent 1050 may be arranged in a high-density format.
- the high-density format may provide, for example, a greater surface area of material to interact with the native anatomy as well as for supporting a cuff, valves, and/or sealing materials attached thereto.
- hooks 1080 and 1090 may function to both anchor stent 1000 in place and to help seal against PV leak.
- FIG. 11 illustrates a prosthetic heart valve 1100 according to another embodiment of the disclosure.
- Prosthetic heart valve 1100 is collapsible and expandable and designed to replace the function of the native mitral valve of a patient.
- prosthetic heart valve 1100 is illustrated in the expanded condition.
- Prosthetic heart valve 1100 may include wire-form stent 1150 , which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Unlike other embodiments described herein, stent 1150 may be formed from a single wire 1152 shaped as desired, as opposed to, for example, a single tube laser cut to a desired shape.
- stent 1150 includes two anchor sections.
- the anchor sections may include a first series of hooks 1180 and a second series of hooks 1190 .
- Each hook 1180 in the first series may extend radially outward from inflow end 1110 of stent 1150 .
- Each hook 1190 in the second series may extend radially outward from outflow end 1112 of stent 1150 .
- a free end of each hook 1190 may be bent back toward inflow end 1110 .
- Prosthetic heart valve 1100 may include a cuff 1164 attached to stent 1150 .
- Cuff 1164 may include a first generally flat portion 1164 a that spans across and is attached to first series of hooks 1180 .
- hooks 1180 extend substantially in a continuous pattern around the circumference of prosthetic heart valve 1100 to provide adequate support for first cuff portion 1164 a .
- first cuff portion 1164 a is positioned on the atrial side of the native valve annulus and may act as a sealing member similar to sealing members 480 and 580 of prosthetic heart valves 400 and 500 , respectively.
- Cuff 1164 may include a second portion 1164 b projecting from flat portion 1164 a in the form of an annular wall surrounding an opening generally in the center of the flat portion. Second portion 1164 b provides structure for the attachment of prosthetic leaflets to prosthetic heart valve 1100 .
- second series of hooks 1190 may be positioned on the ventricular side of the native mitral valve annulus, and may hook around the native mitral valve leaflets to provide anchoring for prosthetic heart valve 1100 .
- two groups of hooks 1190 corresponding to the positions of native mitral valve leaflets may be sufficient for anchoring, without needing hooks 1190 to extend around the entire circumference of stent 1150 .
- cuff 1164 and stent 1150 may be used in combination as a docking station in a two-step delivery system, similar to docking station 600 described above. If used as a docking station, cuff 1164 and stent 1150 may be implanted in the native valve annulus first, followed by the implantation of a traditional prosthetic heart valve or any prosthetic heart valve described herein.
- FIG. 12 is a side view of prosthetic heart valve 1200 according to a further embodiment of the disclosure.
- Prosthetic heart valve 1200 is a collapsible prosthetic heart valve designed to replace the function of the native mitral valve of a patient.
- Prosthetic valve 1200 may be substantially cylindrical, with inflow end 1210 and outflow end 1212 .
- prosthetic valve 1200 may have a low profile so as not to interfere with atrial function in the native valve annulus.
- Prosthetic heart valve 1200 may include stent 1250 , which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.
- Stent 1250 may include a plurality of struts 1252 that form cells 1254 connected to one another in one or more annular rows around the stent.
- Prosthetic heart valve 1200 may also include a valve assembly similar to that described in connection with FIGS. 3A-B .
- the prosthetic leaflets of the valve assembly replace the function of native mitral valve leaflets 136 and 138 . That is, the leaflets coapt with one another to function as a one-way valve.
- the prosthetic leaflets may be attached to stent 1250 at one or more CAFs 1294 .
- Each CAF 1294 may be integral with stent 1250 , for example by laser cutting the entire structure from a tube of material.
- the stents generally include CAFs that extend in the outflow direction and which are connected to a cell at the outflow end of the stent.
- CAFs are generally positioned at an end of the stent. Due to this positioning, and due to the fact that the prosthetic leaflets are attached to the CAFs and are subjected to forces, for example from restricting blood flow in the retrograde direction, the CAFs are prone to deflect inwardly at times during normal operation. This is particularly true when the mitral valve is closed and the pressure in the left ventricle is greater than the pressure in the left atrium.
- CAF 1294 is embedded within a cell 1254 of stent 1250 , rather than being positioned beyond outflow end 1212 .
- CAF 1294 is positioned between inflow end 1210 and outflow end 1212 .
- CAF 1294 has a first end attached to struts 1252 and a second free end pointing toward inflow end 1210 . This configuration may reduce the torque experienced by CAF 1294 due to the forces acting on the prosthetic leaflets attached to CAF 1294 , thereby reducing the deflection of CAF 1294 during normal operation. This, in turn, may result in better coaptation between the prosthetic leaflets and less deterioration of the valve.
- CAF 1294 is embedded within a cell 1254 of stent 1250 , rather than being positioned beyond outflow end 1212 .
- CAF 1294 is positioned between inflow end 1210 and outflow end 1212 .
- CAF 1294 has a first end attached to struts 1252 and a second free end pointing toward inflow end 1210 . This configuration may reduce the torque experienced by CAF 1294 due to the forces acting on the prosthetic leaflets attached to CAF 1294 , thereby reducing the deflection of CAF 1294 during normal operation. This, in turn, may result in better coaptation between the prosthetic leaflets and less deterioration of the valve.
- FIG. 13 illustrates a stent 1300 of a prosthetic heart valve according to still another embodiment of the disclosure.
- Stent 1300 is collapsible and expandable for use in a prosthetic heart valve intended to replace the function of the native mitral valve of a patient.
- stent 1300 is illustrated in its expanded condition.
- Stent 1300 has inflow end 1310 and outflow end 1312 , and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Stent 1300 may include a plurality of struts 1352 that form cells 1354 connected to one another in one or more annular rows around stent 1300 .
- Stent 1300 may be thought of as having an atrial portion 1370 and a ventricular portion 1380 .
- atrial portion 1370 of stent 1300 When implanted in native valve annulus VA, atrial portion 1370 of stent 1300 is positioned on the atrial side of native valve annulus VA, while ventricular portion 1380 of stent 1300 is positioned on the ventricular side of native valve annulus VA.
- Atrial portion 1370 of stent 1300 has a generally bulbous shape and is configured to protrude farther into left atrium 122 than ventricular portion 1380 protrudes into left ventricle 124 .
- the bulbous shape of atrial portion 1370 provides anchoring of stent 1300 , helping to resist the migration of the stent into left ventricle 124 .
- Atrial portion 1370 and the extent of anchoring in left atrium 122 reduce the radial forced needed at native valve annulus VA to keep stent 1300 in place.
- ventricular portion 1380 need only extend minimally into left ventricle 124 , which may reduce interference with chordae tendineae 134 .
- less than a full row of cells 1354 is configured to be positioned in left ventricle 124 when stent 1300 is implanted in native valve annulus VA.
- stents and prosthetic heart valves are generally described for replacement of the mitral other bicuspid valves, variations may be made to these devices to replace tricuspid valves.
- the prosthetic valves may be provided with three leaflets, or more or less leaflets as desired.
- self-expanding prosthetic heart valves or stents the principles described herein are also applicable to prosthetic valves that are not self-expanding, such as balloon expandable prosthetic valves.
- a prosthetic heart valve comprises: a stent having an inflow end, an outflow end, a center portion between the inflow end and the outflow end, a collapsed condition, and an expanded condition; a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets; a first annular sealing member coupled to the inflow end; and a second annular sealing member coupled to the outflow end; and/or
- a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical body having a first end and a second end; a flared portion coupled to the first end of the body and extending radially outwardly from the body and away from the second end of the body when the stent is in the expanded condition; and a plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition, wherein the flared portion and the second free ends of the anchor members are configured to extend away from the second end of the body when the stent is in the collapsed condition; and/or
- a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical center body having a first end and a second end; a first plurality of anchor members each having a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition; and a second plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition, wherein the first and second plurality of anchor members are configured to extend toward the second end of the body when the stent is in the collapsed condition.
- a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical center body having a first end and a second end; a first plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition; and a second plurality of anchor members each having a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition, wherein the first plurality of anchor members extend toward the first end of the body and the second plurality of anchor members extend toward the second end of the body when the stent is in the collapsed condition; and/or
- a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical center body having a first end, a second end, and a longitudinal axis extending between the first end and the second end; a first plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition; and a second plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition, wherein the first plurality of anchor members extend away from the second end of the body and the second plurality of anchor members extend away from the first end of the body when the stent is in the collapsed condition; and/or
- a prosthetic heart valve comprises: a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition, the stent being formed from wire and having a first series of hooks and a second series of hooks; and a cuff coupled to the stent, wherein, when the stent is in the expanded condition, each hook of the first series extends radially outwardly from the stent at the inflow end and each hook of the second series includes a first portion that extends radially outwardly from the stent at the outflow end and a second portion that extends toward the inflow end; and/or
- a prosthetic heart valve comprises: a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition, the stent being formed of a plurality of struts; a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets; and a commissure attachment feature attached to at least one of the plurality of struts and positioned between the inflow end and the outflow end when the stent is in the expanded condition; and/or
Abstract
A prosthetic heart valve may include a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition. The prosthetic valve may also include a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets. The prosthetic valve and/or stent may include features to anchor the prosthetic valve to a native valve annulus and to seal the prosthetic valve with respect to the native valve annulus, such as planar and/or nonplanar annular sealing members coupled to ends of the stent. The stent may include one or more circumferential rows of anchor members or hooks extending radially outwardly from the stent. These hooks may be configured to extend in a particular direction when the stent is in the collapsed condition to facilitate resheathing of the stent if, upon deployment, a user determines the prosthetic heart valve is not positioned optimally.
Description
- The present application claims the benefit of the filing date of U.S. Provisional Patent Application No. 61/970,443 filed Mar. 26, 2014, the disclosure of which is hereby incorporated herein by reference.
- The present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to designs for stent frames for collapsible prosthetic heart valves.
- Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.
- Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve is generally first collapsed or crimped to reduce its circumferential size.
- When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size. For balloon-expandable valves, this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.
- According to one embodiment of the disclosure, a prosthetic heart valve may include a stent having an inflow end, an outflow end, a center portion between the inflow end and the outflow end, a collapsed condition, and an expanded condition. A collapsible and expandable valve assembly may be disposed within the stent and may have a plurality of leaflets. A first annular sealing member may be coupled to the inflow end and a second annular sealing member may be coupled to the outflow end.
- According to another embodiment of the disclosure, a stent having an expanded condition and a collapsed condition may include a substantially cylindrical body having a first end and a second end. A flared portion may be coupled to the first end of the body and may extend radially outwardly from the body and away from the second end of the body when the stent is in the expanded condition. A plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition. The flared portion and the second free ends of the anchor members may be configured to extend away from the second end of the body when the stent is in the collapsed condition.
- According to a further embodiment of the disclosure, a stent having an expanded condition and a collapsed condition may include a substantially cylindrical center body having a first end and a second end. A first plurality of anchor members may each have a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition. A second plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition. The first and second plurality of anchor members may be configured to extend toward the second end of the body when the stent is in the collapsed condition.
- According to still another embodiment of the disclosure, a stent having an expanded condition and a collapsed condition may include a substantially cylindrical center body having a first end and a second end. A first plurality of anchor members each having a first end coupled to the body and a second free end may extend radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition. A second plurality of anchor members each having a first end coupled to the first end of the body and a second free end may extend radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition. The first plurality of anchor members may extend toward the first end of the body and the second plurality of anchor members may extend toward the second end of the body when the stent is in the collapsed condition.
- According to yet another embodiment of the disclosure, a stent having an expanded condition and a collapsed condition may include a substantially cylindrical center body having a first end, a second end, and a longitudinal axis extending between the first end and the second end. A first plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition. A second plurality of anchor members may each have a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition. The first plurality of anchor members may extend away from the second end of the body and the second plurality of anchor members may extend away from the first end of the body when the stent is in the collapsed condition.
- According to yet a further embodiment of the disclosure, a prosthetic heart valve may include a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition. The stent may be formed from wire and may have a first series of hooks and a second series hooks. A cuff may be coupled to the stent. When the stent is in the expanded condition, each hook of the first series may extend radially outwardly from the stent at the inflow end and each hook of the second series may include a first portion that extends radially outwardly from the stent at the outflow end and a second portion that extends toward the inflow end.
- According to an even further embodiment of the disclosure, a prosthetic heart valve may include a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition. The stent may be formed of a plurality of struts. A collapsible and expandable valve assembly may be disposed within the stent and may have a plurality of leaflets. A commissure attachment feature may be attached to at least one of the plurality of struts and may be positioned between the inflow end and the outflow end when the stent is in the expanded condition.
- Various embodiments of the present disclosure are described herein with reference to the drawings, wherein:
-
FIG. 1 is a schematic cutaway representation of a human heart showing a transapical delivery approach; -
FIG. 2 is a schematic representation of a native mitral valve and associated cardiac structures; -
FIG. 3A is a side view of a prosthetic heart valve according to the prior art; -
FIG. 3B is a longitudinal cross-section of the prosthetic heart valve ofFIG. 3A ; -
FIG. 4A is a schematic perspective view of a prosthetic heart valve according to the present disclosure; -
FIG. 4B is a longitudinal cross-section of the prosthetic heart valve ofFIG. 4A ; -
FIG. 4C is a schematic representation of the prosthetic heart valve ofFIG. 4A disposed in a native valve annulus; -
FIG. 5A is a schematic cut-away perspective view of another prosthetic heart valve according to the present disclosure; -
FIG. 5B is a longitudinal cross-section of the prosthetic heart valve ofFIG. 5A ; -
FIG. 5C is a schematic representation of the prosthetic heart valve ofFIG. 5A disposed in a native valve annulus; -
FIG. 6A is a schematic perspective view of a docking station for use with a prosthetic heart valve; -
FIG. 6B is a cross-sectional view of the docking station ofFIG. 6A ; -
FIG. 6C is a schematic representation of the docking station ofFIG. 6A disposed in a native valve annulus with a prosthetic heart valve disposed within the docking station. -
FIG. 7A is a perspective view of a stent of a prosthetic heart valve according to the present disclosure; -
FIG. 7B is a schematic representation of the stent ofFIG. 7A disposed in a native valve annulus; -
FIG. 7C is a perspective view of another stent of a prosthetic heart valve according to the present disclosure; -
FIG. 7D is a schematic representation of the stent ofFIG. 7C disposed in a native valve annulus; -
FIG. 8A is a side view of another stent of a prosthetic heart valve according to the present disclosure; -
FIG. 8B is a schematic representation of the stent ofFIG. 8A disposed in a native valve annulus; -
FIG. 9 is a developed view of a further stent of a prosthetic heart valve according to the present disclosure; -
FIG. 10 is a perspective view of yet another stent of a prosthetic heart valve according to the present disclosure; -
FIG. 11 is a perspective view of another prosthetic heart valve according to the present disclosure; -
FIG. 12 is a side view of a further prosthetic heart valve according to the present disclosure; and -
FIG. 13 is a perspective view of still another stent of a prosthetic heart valve according to the present disclosure. - Various embodiments of the present disclosure will now be described with reference to the appended drawings. It is to be appreciated that these drawings depict only some embodiments of the disclosure and are therefore not to be considered limiting of its scope.
- Blood flows through the mitral valve from the left atrium to the left ventricle. As used herein, the term “inflow end,” when used in connection with a prosthetic mitral heart valve, refers to the end of the heart valve closest to the left atrium when the heart valve is implanted in a patient, whereas the term “outflow end,” when used in connection with a prosthetic mitral heart valve, refers to the end of the heart valve closest to the left ventricle when the heart valve is implanted in a patient. Further, when used herein with reference to a delivery device, the terms “proximal” and “distal” are to be taken as relative to a user using the device in an intended manner. “Proximal” is to be understood as relatively close to the user and “distal” is to be understood as relatively farther away from the user. Also, as used herein, the terms “substantially,” “generally,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified. Generally, materials described as being suitable for components in one embodiment may also be suitable for similar components described in other embodiments.
-
FIG. 1 is a schematic cutaway representation ofhuman heart 100. The human heart includes two atria and two ventricles:right atrium 112 andleft atrium 122, andright ventricle 114 andleft ventricle 124.Heart 100 further includesaorta 110, andaortic arch 120. Disposed between the left atrium and the left ventricle ismitral valve 130.Mitral valve 130, also known as the bicuspid valve or left atrioventricular valve, is a dual-flap that opens as a result of increased pressure inleft atrium 122 as it fills with blood. As atrial pressure increases above that ofleft ventricle 124,mitral valve 130 opens and blood passes intoleft ventricle 124. Blood flows throughheart 100 in the direction shown by arrows “B”. - A dashed arrow, labeled “TA”, indicates a transapical approach of implanting a prosthetic heart valve, in this case to replace the mitral valve. In transapical delivery, a small incision is made between the ribs and into the apex of
left ventricle 124 to deliver the prosthetic heart valve to the target site. A second dashed arrow, labeled “TS”, indicates a transseptal approach of implanting a prosthetic heart valve in which the valve is passed through the septum betweenright atrium 112 andleft atrium 122. Other approaches for implanting a prosthetic heart valve are also possible. -
FIG. 2 is a more detailed schematic representation of nativemitral valve 130 and its associated structures. As previously noted,mitral valve 130 includes two flaps or leaflets,posterior leaflet 136 andanterior leaflet 138, disposed betweenleft atrium 122 andleft ventricle 124. Cord-like tendons, known aschordae tendineae 134, connect the twoleaflets papillary muscles 132. During atrial systole, blood flows from higher pressure inleft atrium 122 to lower pressure inleft ventricle 124. Whenleft ventricle 124 contracts in ventricular systole, the increased blood pressure in the chamber pushesleaflets left atrium 122. Since the blood pressure inleft atrium 122 is much lower than that inleft ventricle 124,leaflets Chordae tendineae 134 prevent the eversion by becoming tense, thus pulling onleaflets -
FIGS. 3A and 3B are a side view and a longitudinal cross-sectional view ofprosthetic heart valve 300 according to the prior art.Prosthetic heart valve 300 is a collapsible prosthetic heart valve designed to replace the function of the native mitral valve of a patient (see nativemitral valve 130 ofFIGS. 1-2 ). Generally,prosthetic valve 300 has a substantially cylindrical shape withinflow end 310 andoutflow end 312. When used to replace nativemitral valve 130,prosthetic valve 300 may have a low profile so as not to interfere with atrial function in the native valve annulus. -
Prosthetic heart valve 300 may includestent 350, which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 350 may include a plurality ofstruts 352 that formcells 354 connected to one another in one or more annular rows around the stent.Cells 354 may all be of substantially the same size around the perimeter and along the length ofstent 350. Alternatively,cells 354 nearinflow end 310 may be larger than the cells nearoutflow end 312.Stent 350 may be expandable to provide a radial force to assist with positioning and stabilizingprosthetic heart valve 300 in the native valve annulus. -
Prosthetic heart valve 300 may also include a substantiallycylindrical valve assembly 360 including a pair of leaflets 362 (FIG. 3B ) attached to a cuff 364 (FIG. 3A ).Leaflets 362 replace the function of nativemitral valve leaflets FIG. 2 . That is,leaflets 362 coapt with one another to function as a one-way valve. Thoughprosthetic heart valve 300 is illustrated as having avalve assembly 360 with twoleaflets 362, it will be appreciated thatprosthetic heart valve 300 may have more than two leaflets when used to replace the mitral valve or other cardiac valves within a patient. Bothcuff 364 andleaflets 362 may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or polymers, such as polytetrafluoroethylene (PTFE), urethanes and the like.Valve assembly 360 may be secured tostent 350 by suturing to struts 352 or by using tissue glue, ultrasonic welding or other suitable methods. - When
prosthetic heart valve 300 is implanted in a patient, for example at the annulus of nativemitral valve 130, it is biased towards an expanded condition, providing radial force to anchor the valve in place. However, if the radial force is too high, damage may occur to heart tissue. If, instead, the radial force is too low, the heart valve may move from its implanted position, for example, into eitherleft ventricle 124 or leftatrium 122, requiring emergency surgery to remove the displaced valve. The potential for such movement may be heightened in mitral valve applications, particularly if a low profile valve is used. - Another potential issue with prosthetic heart valves is inadequate sealing between the prosthetic valve and the native tissue. For example, if
prosthetic heart valve 300 is implanted at the annulus ofmitral valve 130 in a patient, improper or inadequate sealing may result in blood flowing fromleft ventricle 124 intoleft atrium 122, even ifleaflets 362 ofvalve assembly 360 are working properly. This may occur, for example, if blood flows in a retrograde fashion between the outer perimeter ofprosthetic heart valve 300 and the native tissue at the site of implantation. This phenomenon is known as perivalvular (or paravalvular) leak (“PV leak”). -
FIGS. 4A and 4B illustrate aprosthetic heart valve 400 according to one embodiment of the disclosure in perspective and longitudinal cross-section views, respectively.Prosthetic heart valve 400 is a collapsible prosthetic heart valve designed to replace the function of the native mitral valve of a patient. Generally,prosthetic valve 400 hasinflow end 410 andoutflow end 412. -
Prosthetic heart valve 400 may includestent 450, which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 450 may include a plurality ofstruts 452 that formcells 454 connected to one another in one or more annular rows around the stent.Stent 450 may be radially expandable to provide a radial force to assist with positioning and stabilizingprosthetic heart valve 400 in the native mitral valve annulus.Stent 450 may be substantially cylindrically shaped when in the expanded condition. -
Prosthetic heart valve 400 may also includevalve assembly 460 including a pair ofleaflets 462.Leaflets 462 function similarly toleaflets 362 described above in connection withFIG. 3B , and more or fewer leaflets may be used in other applications. - A number of sealing elements may be provided on
prosthetic heart valve 400. In particular,prosthetic heart valve 400 may include afirst sealing ring 480 positioned atinflow end 410 and asecond sealing ring 490 positioned atoutflow end 412. Each sealingring rings rings rings rings inflow end 410 andoutflow end 412, respectively, by, for example, sutures, adhesives, ultrasonic welding or other suitable methods. Alternatively, if sealing rings 480 and 490 are formed of the same material asstent 450, sealingrings stent 450. - Each sealing
ring stent 450 so that blood may flow through the stent. Sealing rings 480 and 490 may each have an outer diameter that is greater than the diameter ofstent 450 when in the expanded condition. Whenstent 450 is in the expanded condition, sealingrings FIG. 4C showsprosthetic heart valve 400 implanted within native valve annulus VA betweenleft atrium 122 andleft ventricle 124. In the implanted position,first sealing ring 480 is positioned on the atrial side of native valve annulus VA whilesecond sealing ring 490 is positioned on the ventricular side of native valve annulus VA. Sealing rings 480 and 490 may help prevent PV leak by preventing blood from flowing fromleft ventricle 124 toleft atrium 122 between the native valve annulus VA and the outer perimeter ofprosthetic heart valve 400. This function may be enhanced once tissue begins to grow into first sealingring 480 andsecond sealing ring 490. - In addition to helping prevent PV leak, sealing
ring 480 may provide an anchoring effect, helping to preventprosthetic heart valve 400 from migrating towardleft ventricle 124. Similarly,second sealing ring 490 may also provide an anchoring effect, helping to preventprosthetic heart valve 400 from migrating towardleft atrium 122. This additional anchoring ability may reduce the radial force required ofstent 450 to keepprosthetic heart valve 400 secured in native valve annulus VA, which, in turn, may allowstent 450 to have a smaller fully expanded diameter than traditional stents. This reduction in size may be possible, in part, due to a reduction or elimination of the need to have a relatively large stent frame to maximize the range of anatomies which could accept the stent and still have enough radial force to hold the stent in place. The relatively smaller diameter which may be possible due to the above-described features may result in lower hydrodynamic load onprosthetic heart valve 400, which may reduce the stresses onvalve assembly 460 and which also may reduce the strain on thematerial forming stent 450. -
FIGS. 5A and 5B illustrate aprosthetic heart valve 500 according to another embodiment of the disclosure.Prosthetic heart valve 500 is similar toprosthetic heart valve 400 in certain respects. For example,prosthetic heart valve 500 may includestent 550, which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 550 may include a plurality ofstruts 552 that formcells 554 connected to one another in one or more annular rows around the stent.Stent 550 may be radially expandable to provide a radial force to assist with positioning and stabilizingprosthetic heart valve 500 in the native valve annulus.Stent 550 has the general shape of a cylinder, except that it is bowed inwardly frominflow end 510 andoutflow end 512 toward the center. In other words,stent 550 has a concave shape, wherein the center ofstent 550 has a smaller diameter than that ofinflow end 510 andoutflow end 512 when in the expanded condition. -
Prosthetic heart valve 500 may also includevalve assembly 560 including a pair ofleaflets 562.Leaflets 562 function similarly toleaflets 362 described above in connection withFIG. 3B , and more or fewer leaflets may be used in other applications. -
Prosthetic heart valve 500 may also include a number of sealing elements. In particular,prosthetic heart valve 500 may include afirst sealing ring 580 positioned atinflow end 510 and asecond sealing ring 590 positioned atoutflow end 512. Sealing rings 580, 590 may be generally similar to sealingrings ring 580 is curved towardoutflow end 512 andsecond sealing ring 590 is curved towardinflow end 510. In other words, sealingrings stent 550 is in the expanded condition. Sealing rings 580, 590 may be formed of the same biocompatible materials described above for forming sealing rings 480 and 490, and may be attached toinflow end 510 andoutflow end 512, respectively, in the same manner as sealingrings - Each sealing
ring stent 550 so that blood may flow through the stent. As described above, sealingrings stent 550 to which the rings are attached. In other words, the outer perimeter offirst sealing ring 580 is closer to outflow end 512 than the inner perimeter of that sealing ring. Similarly, the outer perimeter ofsecond sealing ring 590 is closer to inflow end 510 than the inner perimeter of that sealing ring. However, other shapes and sizes may be suitable depending on the particular anatomy of the patient. -
FIG. 5C showsprosthetic heart valve 500 implanted within native valve annulus VA betweenleft atrium 122 andleft ventricle 124. In the implanted position,first sealing ring 580 is positioned on the atrial side of native valve annulus VA whilesecond sealing ring 590 is positioned on the ventricular side of native valve annulus VA. In these positions, sealingrings left ventricle 124 toleft atrium 122 between the native valve annulus VA and the outer perimeter ofprosthetic heart valve 500. Once tissue begins to grow into first sealingring 580 andsecond sealing ring 590, PV leak may be mitigated to an even greater extent. - In addition to helping prevent PV leak,
first sealing ring 580 may provide an anchoring effect, helping to preventprosthetic heart valve 500 from migrating towardleft ventricle 124. Similarly,second sealing ring 590 may also provide an anchoring effect, helping to preventprosthetic heart valve 500 from migrating towardleft atrium 122. The curvature of sealingrings prosthetic heart valve 500 interacts with the anatomy and how stresses are distributed invalve 500. The above-described curvature may have an enhanced effect on sealing and anchoring in comparison to a relatively flat or planar sealing ring. This may be due, in part, to the anatomy near the implant site having generally non-planar surfaces. Further, the curvature of sealingrings stent 550 may provide a greater contact area betweenstent 550 and the native valve annulus VA. -
FIGS. 6A and 6B illustrate a prosthetic heartvalve docking station 600 according to one embodiment of the disclosure in perspective and longitudinal cross-sectional views, respectively. As is described below,docking station 600 may first be implanted in a native valve annulus, and a prosthetic heart valve may be subsequently implanted indocking station 600. -
Docking station 600 hasinflow end 610 andoutflow end 612, and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Docking station 600 may alternatively be made of a material that is not self-expandable, such as stainless steel, which may be expanded with the use of a separate expandable structure, such as a balloon. -
Docking station 600 may have the general form of a hollow tube with acylindrical center section 670 and anchoring members extending radially outwardly atinflow end 610 andoutflow end 612. For example, the illustrated embodiment ofdocking station 600 includesfirst anchor rim 680 andsecond anchor rim 690. The particular shape of eachanchor rim first anchor rim 680 may have a cylindricalouter surface 682 that is substantially concentric tocylindrical center section 670. Oneend surface 684 of anchor rim 680 coextensive withinflow end 610 may lie in a plane perpendicular to the axis of rotation ofcentral section 670. Theother end surface 686 ofanchor rim 680 may be inclined at an oblique angle to the axis of rotation ofcentral section 670.Second anchor rim 690 may have a similar structure. That is,second anchor rim 690 may have a cylindricalouter surface 692 that is substantially concentric tocenter section 670. Oneend surface 694 of anchor rim 690 coextensive withoutflow end 612 may lie in a plane perpendicular to the axis of rotation ofcenter section 670, while theother end surface 696 ofanchor rim 690 may be inclined at an oblique angle to that axis of rotation. The inclined surfaces of anchor rims 680 and 690 may provide better contact with a native valve annulus, but may be varied and still be within the scope of this disclosure. -
FIG. 6C showsdocking station 600 implanted within native valve annulus VA betweenleft atrium 122 andleft ventricle 124. In the implanted position,first anchor rim 680 is positioned on the atrial side of native valve annulus VA while anchor rim 690 is positioned on the ventricular side of native valve annulus VA. Anchor rims 680 and 690 may provide an anchoring effect, helping preventdocking station 600 from migrating towardleft ventricle 124 or leftatrium 122. Oncedocking station 600 has been implanted as described, prosthetic heart valve PHV may be assembled to the docking station. - A number of benefits may result from using a two-step process in which
docking station 600 is first implanted within native valve annulus VA and then prosthetic heart valve PHV is assembled todocking station 600. For example, when implanted, prosthetic heart valve PHV, which may take the form of any traditional prosthetic heart valve or any of the embodiments disclosed herein, will encounter a predictable environment. That is, the variability in anatomy from one patient to another will have less effect on the positioning and functioning of prosthetic heart valve PHV, because prosthetic heart valve PHV will interact directly withdocking station 600 rather than with the anatomy of native valve annulus VA. -
FIG. 7A illustrates astent 700 of a prosthetic heart valve according to one embodiment of the disclosure.Stent 700 is collapsible and expandable for use in a prosthetic heart valve intended to replace the function of the native mitral valve of a patient. InFIG. 7A ,stent 700 is illustrated in its expanded condition. The remaining components that would be attached tostent 700 to form a prosthetic heart valve, such as leaflets and a cuff, are omitted from the figures for clarity. -
Stent 700 hasinflow end 710 andoutflow end 712, and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 700 may include a plurality ofstruts 752 that form cells connected to one another in one or more annular rows around the stent. -
Stent 700 may be thought of as having at least three main portions. Atinflow end 710 is flaredportion 770, which flares radially outwardly in a direction away fromoutflow end 712. Flaredportion 770 may include one or more circumferential rows of relativelysmall cells 754 a. Eachcell 754 a is formed from a group ofstruts 752 that defines a geometric shape having a relatively small area, in this case generally a diamond shape. -
Stent 700 also includes a substantiallycylindrical body 780 that extends from flaredportion 770 to outflow end 712 of the stent.Body 780 may include one or more circumferential rows of relativelylarge cells 754 b. Eachcell 754 b is formed from a group ofstruts 752 that defines a geometric shape having a relatively large area, in this case generally a diamond shape.Struts 752 forminglarger cells 754 b may be thicker and stronger thanstruts 752 formingsmaller cells 754 a. Rows of relativelysmall cells 754 a may be thought of as being a high-density arrangement of cells, while rows of relativelylarge cells 754 b may be thought as being a low-density arrangement of cells. -
Stent 700 also includes a portion with anchor members, in this case hooks 790.Hooks 790 are formed ofstruts 752 that extend radially outwardly towardinflow end 710.Hooks 790 may be integral withstent 700, being formed from the same single piece of starting material, and may be connected tostent 700 anywhere onbody 780. It should be noted that the term hooks may include other anchoring structures, for example barbs or clips. - When being used in a prosthetic heart valve for replacing the native mitral valve of a patient,
stent 700 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. The delivery device may, for example, be inserted through the apex of the heart (transapical delivery) or through the femoral artery and passed through the vasculature to the implant site (transfemoral delivery). Once the delivery device is near the site of implantation, the sheath or othermember compressing stent 700 may be slowly retracted to revealstent 700 and allow it to expand to the expanded condition. If a transapical method is used with a split sheath, as a proximal portion of the sheath is retracted proximally, hooks 790 are first released from the proximal portion of the sheath and expand. The release ofhooks 790 may be performed inleft ventricle 124 and then pushed distally untilhooks 790 catchnative leaflets hooks 790 may be performed inleft atrium 122, then pulled proximally intoleft ventricle 124 and then pushed back to catchnative leaflets hooks 790 may be accomplished with other types of sheaths, for example with a double proximal sheath with a slot or other opening in the inner sheath to allowhooks 790 to deploy first. It should be noted that in the collapsed condition, hooks 790 point towardinflow end 710, rather than towardoutflow end 712. In other words, hooks 790 (as well as flared portion 770) are folded towardleft atrium 122 during deployment, such that hooks 790 may gradually expand outwardly as the delivery sheath is slowly retracted. If, on the other hand, hooks 790 were delivered folded towardleft ventricle 124, once the delivery sheath clearedhooks 790, the hooks would suddenly flip nearly 180 degrees, possibly causing trauma to native valve annulus VA. - Once
hooks 790 are in place, the distal portion of the split sheath may be pushed distally to release flaredportion 770. As it is released, flaredportion 770 begins to expand on the atrial side of the native valve annulus VA.Prosthetic heart valve 700 is illustrated after full release inFIG. 7B . The inclusion ofsmaller cells 754 a in a high-density arrangement in flaredportion 770 allows for relatively greater tissue ingrowth and also facilitates creating and maintaining the flared shape of flaredportion 770, which provides for better alignment and sealing atinflow end 710 ofstent 700. - With
body 780 and hooks 790 in the expanded condition, hooks 790 hook around the native anterior and posterior mitral valve leaflets, helpingsecure stent 700 in place. Becausebody 780 is generally comprised oflarger cells 754 b formed ofthicker struts 752 instead ofsmaller cells 754 a formed of thinner struts,body 780 is somewhat more rigid and facilitates better anchoring byhooks 790. This better anchoring may be partly due to the fact that hooks 790 are connected tobody 780, and may also be formed of relativelythick struts 752 to provide additional strength. In addition, becausehooks 790 point towardinflow end 710 during delivery and deployment,stent 700 may be resheathed any time prior to release of flaredportion 770 into the expanded condition, for example by pushing a proximal portion of a split sheath distally before the distal portion of the split sheath is released. If a double proximal sheath were used,stent 700 could be resheathed at any time prior to release of the entire stent into the expanded condition. - Referring back to
FIG. 7A ,stent 700 may include one or more commissure attachment features (“CAFs”) 792 and one ormore retention members 794 as are known in the art. EachCAF 792 provides a site for the prosthetic valve leaflets to be attached tostent 700. Eachretention member 794 provides a feature for connectingstent 700 to the delivery device, the connection being maintained untilstent 700 is fully released from the delivery device. It should further be noted that, althoughhooks 790 are shown as being formed integrally withstent 700, hooks 790 may be formed separately of any one or a combination of a variety of materials, including for example Nitinol, polymers such as polyvinyl alcohol (“PVA”), and tissues such as bovine or porcine cardiac tissue. -
FIG. 7C illustrates an alternate embodiment ofstent 700′ of a prosthetic heart valve according to another embodiment of the disclosure. (It should be noted inFIG. 7C that an opaque strip of material is positioned withinstent 700′ to more clearly demonstrate features of the stent. This strip of material forms no part ofstent 700′ or the prosthetic valve incorporating the stent.)Stent 700′ has features in common withstent 700. For example,stent 700′ is collapsible and expandable, hasinflow end 710′ and outflow end 712′, and may be formed from biocompatible materials that are capable of self-expansion.Stent 700′ may include a plurality ofstruts 752′ that form cells connected to one another in one or more annular rows around the stent.Stent 700′ includes flaredportion 770′ atinflow end 710′. Flaredportion 770′ extends radially outwardly in a direction away fromoutflow end 712′ and may include one or more circumferential rows ofcells 754′.Stent 700′ may also include a substantiallycylindrical body 780′ that extends fromoutflow end 712′ towardinflow end 710′.Body 780′ may include one or more circumferential rows ofcells 754′. Eachcell 754′ may be formed from a group ofstruts 752′ that defines a general diamond shape. -
Stent 700′ may also include a portion with anchor members, such ashooks 790′.Hooks 790′ may be formed ofstruts 752′ that extend radially outwardly towardinflow end 710′, and then angle back such that they extend generally parallel to a longitudinal axis ofstent 700′.Hooks 790′ may be integral withstent 700′, being formed from the same single piece of starting material, and may be connected tostent 700′ anywhere onbody 780′.Hooks 790′ may be generally similar tohooks 790 ofstent 700, with at least two distinctions. First, as described above, rather than extend at a generally constant angle radially outward frombody 780′, hooks 790′ extend at a first angle and then angle back such that a free end of eachhook 790′ is generally parallel to the longitudinal axis ofstent 700′. As illustrated inFIG. 7D , this configuration may provide a better clamping action ofnative valve leaflets hooks 790′ need not be exactly parallel to the longitudinal axis and variations from parallel may exist. Second, the free end ofhooks 790′ may be rounded or otherwise curved. Compared to a free end with a sharp angle, hooks 790′ may be less traumatic to the native tissue. - Flared
portion 770′ may also vary from flaredportion 770 ofstent 700, at least in that flaredportion 770′ is not connected tobody 780′ at the tip of acell 754′. Rather than being connected to the portion ofbody 780′ that is closest to inflow end 710′, flaredportion 770′ is connected tobody 780′ farther towardoutflow end 712′. In the illustrated embodiment, flaredportion 770′ is connected tobody 780′ at a point where twoadjacent cells 754′ in the same circumferential row meet. This configuration results in some overlap in the longitudinal direction of flaredportion 770′ andbody 780′. When implanted, as illustrated inFIG. 7D , flaredportion 770′ makes contact with native valve annulus VA, while the points onbody 780′ closest to inflow end 710′ extend a distance intoleft atrium 122. Because structures including a cuff and valve assembly (not illustrated inFIGS. 7C-D ) would be attached tobody 780′, retaining the cylindrical geometry ofbody 780′ near the point of contact between flaredportion 770′ and native valve annulus VA may help more evenly distribute the pressures and forces exerted onstent 700′ during normal operation. The delivery and deployment of a prosthetic heartvalve incorporating stent 700′ may be substantially the same as described above in relation tostent 700. -
FIG. 8A illustrates astent 800 of a prosthetic heart valve according to another embodiment of the disclosure.Stent 800 is collapsible and expandable for use in a prosthetic heart valve for replacing the function of the native mitral valve of a patient. InFIG. 8A ,stent 800 is illustrated in its expanded condition. -
Stent 800 hasinflow end 810 andoutflow end 812, and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 800 may include a plurality ofstruts 852 that formcells 854 connected to one another in one or more annular rows around the stent. -
Stent 800 includes a substantiallycylindrical body 870 and two anchor sections. The anchor sections may take the form of a first circumferential row ofhooks 880 and a second circumferential row ofhooks 890. Eachhook 880 in the first circumferential row has a first end attached to inflow end 810 ofstent 800 and a free end extending radially outwardly and towardoutflow end 812 ofstent 800 in the expanded condition. (It should be noted inFIG. 8A that an opaque strip of material is positioned between first circumferential row ofhooks 880 andbody 870 to more clearly demonstrate their relative radial positioning. This strip of material forms no part ofstent 800 or the prosthetic valve incorporating the stent.) Eachhook 890 in the second circumferential row has a first end attached tobody 870 ofstent 800 at a spaced distance frominflow end 810 and a free end extending radially outwardly and towardoutflow end 812 in the expanded condition. - When being used in a prosthetic heart valve for replacing the native mitral valve of a patient,
stent 800 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. In the collapsed condition, the free ends ofhooks 880 in the first circumferential row and the free ends ofhooks 890 in the second circumferential row all point towardoutflow end 812 ofstent 800. If a transfemoral or transaortic delivery route is used, once at the site of implantation, asheath covering stent 800 may be retracted such thatoutflow end 812 ofstent 800 expands first. Asoutflow end 812 ofstent 800 expands and the sheath is retracted further, hooks 890 in the second circumferential row are released from constraint. Upon further retraction of the sheath, the remainder ofstent 800, along withhooks 880 in the first circumferential row, are released from the constraint of the sheath and expand. -
FIG. 8B illustratesstent 800 in its fully expanded state within native mitral valve annuls VA. In particular, hooks 880 in the first circumferential row are positioned on, and in contact with, the atrial side of native valve annulus VA.Hooks 890 in the second circumferential row are positioned on, and in contact with, the ventricular side of native valve annulus VA. This positioning facilitates anchoring ofstent 800 in native valve annulus VA, and helps to prevent PV leak. - Because the free ends of
hooks outflow end 812 during deployment,stent 800 may be resheathed any time prior to release of the entire stent into the expanded condition. Similarly, because of this orientation ofhooks hooks stent 800 from the sheath. It should be understood that a similar result may be achieved with a transapical delivery route if a sheath with a distal pull-off is used. Further, other routes not specifically mentioned herein, such through the inferior vena cava, may be used with an appropriate sheath to allow the desired order of release and resheathing capabilities, as would be understood by one of ordinary skill in the art. - Referring back to
FIG. 8A ,stent 800 may include one or more CAFs 892 and one ormore retention members 894 as are known in the art. It should be noted thatretention members 894 are oninflow end 810 in this case becauseinflow end 810 is intended to be released at the end of deployment. This is in contrast toretention members 794 ofstent 700 inFIG. 7A , which are onoutflow end 712 becauseoutflow end 712 ofstent 700 is intended to be released at the end of deployment. -
FIG. 9 illustratesstent 900 of a prosthetic heart valve according to a further embodiment of the disclosure.Stent 900 is collapsible and expandable for use in a prosthetic heart valve intended to replace the function of the native mitral valve of a patient. InFIG. 9 ,stent 900 is illustrated as if it were cut longitudinally and laid out in a flat, expanded condition. -
Stent 900 hasinflow end 910 andoutflow end 912 and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 900 may include a plurality ofstruts 952 that formcells 954 connected to one another in one or more annular rows around the stent. -
Stent 900 includes a substantiallycylindrical body 970 and two anchor sections. The anchor sections may take the form of a first circumferential row ofhooks 980 and a second circumferential row ofhooks 990. Eachhook 980 in the first circumferential row has a first end attached to inflow end 910 ofstent 900 and a free end extending radially outwardly and towardoutflow end 912 ofstent 900 when in the expanded condition. Eachhook 990 in the second circumferential row has a first end attached tobody 970 ofstent 900 at a spaced distance frominflow end 910 and a free end extending radially outwardly and towardinflow end 910 ofstent 900 when in the expanded condition. It should be noted that, when in the expanded condition, hooks 980 and 990 may extend generally perpendicular tostent body 970 or at an oblique angle towards eitherinflow end 910 oroutflow end 912. It should also be noted that each circumferential row ofhooks more hooks 990 may be provided to anchorstent 900 to native anterior and posterior mitral valve leaflets, with a number ofcells 954 withouthooks 990 being positioned between the groups. - When used in a prosthetic heart valve intended to replace the native mitral valve of a patient,
stent 900 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. In the collapsed condition, the free ends ofhooks 980 in the first circumferential row and the free ends ofhooks 990 in the second circumferential row all point toward the center ofstent 900. This may be particularly useful when a split sheath is being used to deploystent 900. - Generally, a split sheath refers to a sheath that is configured to house
stent 900 in a collapsed condition and a portion of the sheath housing the stent may move distally with respect to the stent while the remainder of the sheath housing the stent may remain stationary or may independently move proximally with respect to the stent. With a splitsheath inflow end 910 may be exposed before or afteroutflow end 912. In other words, distal movement of one portion of the sheath housing will exposeinflow end 910, while proximal movement of the remainder of the sheath housing will exposeoutflow end 912. Althoughhooks hooks 990 inleft ventricle 124 and then pushstent 900 such that hooks 990 engagenative valve leaflets hooks 980 may be deployed inleft atrium 122 while keeping a portion of the distal delivery sheath coveringinflow end 910. Once proper positioning is verified, the distal sheath may be pushed beyondinflow end 910 and the proximal sheath may be pulled off theoutflow end 912 to fully releasestent 900. When in the fully expanded condition,stent 900 may be anchored to the native mitral valve in a manner similar to that illustrated inFIG. 8B . However, unlike other embodiments described herein, the configurations ofhooks entire stent 900 to be resheathed prior to the full release of the stent when a split sheath device is used for deployment. -
FIG. 10 illustrates astent 1000 of a prosthetic heart valve according to a further embodiment of the disclosure.Stent 1000 is collapsible and expandable for use in a prosthetic heart valve for replacing the function of the native mitral valve of a patient. InFIG. 10 ,stent 1000 is illustrated in the expanded condition. -
Stent 1000 hasinflow end 1010 andoutflow end 1012 and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 1000 may include a plurality ofstruts 1052 that formcells 1054 connected to one another in one or more annular rows around the stent. -
Stent 1000 includes a substantiallycylindrical body 1070 and two anchor sections. The anchor sections may take the form of a first circumferential row ofhooks 1080 and a second circumferential row ofhooks 1090. Eachhook 1080 in the first circumferential row has a first end attached toinflow end 1010 ofstent 1000 and a free end extending radially outwardly. Eachhook 1090 in the second circumferential row has a first end attached tooutflow end 1012 ofstent 1000 and a free end extending radially outwardly. In the expanded condition, hooks 1080 and 1090 may extend substantially perpendicularly to the central axis ofbody 1070 or, for each circumferential row, the hooks in that circumferential row may extend at an angle towards the hooks in the other circumferential row. Eachhook 1080 may be a part of asingle cell 1054 that is also part ofbody 1070. Similarly, eachhook 1090 may be part of asingle cell 1054 that is also part ofbody 1070. The first circumferential row ofhooks 1080 may extend continuously around the perimeter ofinflow end 1010. In other words, eachcell 1054 atinflow end 1010 may form ahook 1080. However, it should be understood that hooks 1080 need not extend continuously around the perimeter ofinflow end 1010 andcells 1054 not forming a hook may be interposed between cells that do form hooks. The second circumferential row ofhooks 1090 is preferably not continuous. In other words, at least somecells 1054 atoutflow end 1012 preferably do not from ahook 1090. For example,cells 1054 terminating in aCAF 1094 preferably do not form ahook 1090, otherwise the ability to attach a prosthetic valve tostent 1000 could be hindered. - When used in a prosthetic heart valve to replace the native mitral valve of a patient,
stent 1000 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. In the collapsed condition, the free ends ofhooks 1080 in the first circumferential row point away fromoutflow end 1012 and the free ends ofhooks 1090 in the second circumferential row point away frominflow end 1010. - Depending on the particular mode of delivery and sheath used to deploy
stent 1000,stent 1000 may be only partially resheathable. In other words, if the hooks in only one circumferential row have been deployed from the delivery device,stent 1000 may be resheathed to reposition its associated prosthetic valve. If, on the other hand, the hooks in both circumferential rows have been deployed from the delivery device,stent 1000 may no longer be resheathed even ifretention members 1094 are still connected to the delivery device. Despite being only partially resheathable, the configuration ofstent 1000 may provide a number of benefits. For example,stent 1000 generally has a less complex structure than, for example,stents hooks cells 1054 ofbody 1070, allcells 1000 of stent 1050 may be arranged in a high-density format. The high-density format may provide, for example, a greater surface area of material to interact with the native anatomy as well as for supporting a cuff, valves, and/or sealing materials attached thereto. In addition, when in the crimped condition, there is no overlap between either row of hooks andcylindrical body 1070, permitting a smaller crimp profile to be obtained. Similarly tostents stent 1000 is properly positioned in native valve annulus VA, hooks 1080 and 1090 may function to bothanchor stent 1000 in place and to help seal against PV leak. -
FIG. 11 illustrates aprosthetic heart valve 1100 according to another embodiment of the disclosure.Prosthetic heart valve 1100 is collapsible and expandable and designed to replace the function of the native mitral valve of a patient. InFIG. 11 ,prosthetic heart valve 1100 is illustrated in the expanded condition. -
Prosthetic heart valve 1100 may include wire-form stent 1150, which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Unlike other embodiments described herein,stent 1150 may be formed from asingle wire 1152 shaped as desired, as opposed to, for example, a single tube laser cut to a desired shape. In the illustrated embodiment,stent 1150 includes two anchor sections. In particular, the anchor sections may include a first series ofhooks 1180 and a second series ofhooks 1190. Eachhook 1180 in the first series may extend radially outward frominflow end 1110 ofstent 1150. Eachhook 1190 in the second series may extend radially outward fromoutflow end 1112 ofstent 1150. A free end of eachhook 1190 may be bent back towardinflow end 1110. -
Prosthetic heart valve 1100 may include acuff 1164 attached tostent 1150.Cuff 1164 may include a first generallyflat portion 1164 a that spans across and is attached to first series ofhooks 1180. Preferably, hooks 1180 extend substantially in a continuous pattern around the circumference ofprosthetic heart valve 1100 to provide adequate support forfirst cuff portion 1164 a. Whenprosthetic heart valve 1100 is implanted,first cuff portion 1164 a is positioned on the atrial side of the native valve annulus and may act as a sealing member similar to sealingmembers prosthetic heart valves Cuff 1164 may include asecond portion 1164 b projecting fromflat portion 1164 a in the form of an annular wall surrounding an opening generally in the center of the flat portion.Second portion 1164 b provides structure for the attachment of prosthetic leaflets toprosthetic heart valve 1100. Whenprosthetic heart valve 1100 is implanted, second series ofhooks 1190 may be positioned on the ventricular side of the native mitral valve annulus, and may hook around the native mitral valve leaflets to provide anchoring forprosthetic heart valve 1100. With this configuration, two groups ofhooks 1190 corresponding to the positions of native mitral valve leaflets may be sufficient for anchoring, without needinghooks 1190 to extend around the entire circumference ofstent 1150. - While prosthetic leaflets may be attached to
cuff 1164 andstent 1150 to form a fully functioning prosthetic heart valve,cuff 1164 andstent 1150 may be used in combination as a docking station in a two-step delivery system, similar todocking station 600 described above. If used as a docking station,cuff 1164 andstent 1150 may be implanted in the native valve annulus first, followed by the implantation of a traditional prosthetic heart valve or any prosthetic heart valve described herein. -
FIG. 12 is a side view ofprosthetic heart valve 1200 according to a further embodiment of the disclosure.Prosthetic heart valve 1200 is a collapsible prosthetic heart valve designed to replace the function of the native mitral valve of a patient.Prosthetic valve 1200 may be substantially cylindrical, withinflow end 1210 andoutflow end 1212. When used to replace nativemitral valve 130,prosthetic valve 1200 may have a low profile so as not to interfere with atrial function in the native valve annulus. -
Prosthetic heart valve 1200 may includestent 1250, which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 1250 may include a plurality ofstruts 1252 that formcells 1254 connected to one another in one or more annular rows around the stent. -
Prosthetic heart valve 1200 may also include a valve assembly similar to that described in connection withFIGS. 3A-B . The prosthetic leaflets of the valve assembly replace the function of nativemitral valve leaflets stent 1250 at one ormore CAFs 1294. EachCAF 1294 may be integral withstent 1250, for example by laser cutting the entire structure from a tube of material. - For prosthetic mitral valves, the stents generally include CAFs that extend in the outflow direction and which are connected to a cell at the outflow end of the stent. In other words, CAFs are generally positioned at an end of the stent. Due to this positioning, and due to the fact that the prosthetic leaflets are attached to the CAFs and are subjected to forces, for example from restricting blood flow in the retrograde direction, the CAFs are prone to deflect inwardly at times during normal operation. This is particularly true when the mitral valve is closed and the pressure in the left ventricle is greater than the pressure in the left atrium.
- As illustrated in
FIG. 12 ,CAF 1294 is embedded within acell 1254 ofstent 1250, rather than being positioned beyondoutflow end 1212. In other words,CAF 1294 is positioned betweeninflow end 1210 andoutflow end 1212.CAF 1294 has a first end attached tostruts 1252 and a second free end pointing towardinflow end 1210. This configuration may reduce the torque experienced byCAF 1294 due to the forces acting on the prosthetic leaflets attached toCAF 1294, thereby reducing the deflection ofCAF 1294 during normal operation. This, in turn, may result in better coaptation between the prosthetic leaflets and less deterioration of the valve. - As illustrated in
FIG. 12 ,CAF 1294 is embedded within acell 1254 ofstent 1250, rather than being positioned beyondoutflow end 1212. In other words,CAF 1294 is positioned betweeninflow end 1210 andoutflow end 1212.CAF 1294 has a first end attached tostruts 1252 and a second free end pointing towardinflow end 1210. This configuration may reduce the torque experienced byCAF 1294 due to the forces acting on the prosthetic leaflets attached toCAF 1294, thereby reducing the deflection ofCAF 1294 during normal operation. This, in turn, may result in better coaptation between the prosthetic leaflets and less deterioration of the valve. -
FIG. 13 illustrates astent 1300 of a prosthetic heart valve according to still another embodiment of the disclosure.Stent 1300 is collapsible and expandable for use in a prosthetic heart valve intended to replace the function of the native mitral valve of a patient. InFIG. 13 ,stent 1300 is illustrated in its expanded condition. -
Stent 1300 hasinflow end 1310 andoutflow end 1312, and may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol.Stent 1300 may include a plurality ofstruts 1352 that formcells 1354 connected to one another in one or more annular rows aroundstent 1300. -
Stent 1300 may be thought of as having anatrial portion 1370 and aventricular portion 1380. When implanted in native valve annulus VA,atrial portion 1370 ofstent 1300 is positioned on the atrial side of native valve annulus VA, whileventricular portion 1380 ofstent 1300 is positioned on the ventricular side of native valve annulus VA.Atrial portion 1370 ofstent 1300 has a generally bulbous shape and is configured to protrude farther intoleft atrium 122 thanventricular portion 1380 protrudes intoleft ventricle 124. The bulbous shape ofatrial portion 1370 provides anchoring ofstent 1300, helping to resist the migration of the stent intoleft ventricle 124. The bulbous shape ofatrial portion 1370 and the extent of anchoring inleft atrium 122 reduce the radial forced needed at native valve annulus VA to keepstent 1300 in place. As a result,ventricular portion 1380 need only extend minimally intoleft ventricle 124, which may reduce interference withchordae tendineae 134. For example, as illustrated, less than a full row ofcells 1354 is configured to be positioned inleft ventricle 124 whenstent 1300 is implanted in native valve annulus VA. - Various modifications may be made to the embodiments disclosed herein without departing from the scope of the disclosure. For example, although stents and prosthetic heart valves are generally described for replacement of the mitral other bicuspid valves, variations may be made to these devices to replace tricuspid valves. Thus, the prosthetic valves may be provided with three leaflets, or more or less leaflets as desired. Similarly, although generally described as self-expanding prosthetic heart valves or stents, the principles described herein are also applicable to prosthetic valves that are not self-expanding, such as balloon expandable prosthetic valves.
- According to one embodiment of the disclosure, a prosthetic heart valve comprises: a stent having an inflow end, an outflow end, a center portion between the inflow end and the outflow end, a collapsed condition, and an expanded condition; a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets; a first annular sealing member coupled to the inflow end; and a second annular sealing member coupled to the outflow end; and/or
-
- the first and second sealing members each have a diameter greater than a diameter of the stent when the stent is in the expanded condition; and/or
- the stent is substantially cylindrical in the expanded condition; and/or
- the first sealing member has a substantially planar configuration when the stent is in the expanded condition; and/or
- the inflow end and the outflow end of the stent each has a diameter greater than a diameter of the center portion of the stent when the stent is in the expanded condition; and/or
- the first sealing member is substantially nonplanar when the stent is in the expanded condition; and/or
- an outer perimeter of the first sealing member is closer to the outflow end than an inner perimeter of the first sealing member when the stent is in the expanded condition.
- According to another embodiment of the disclosure, a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical body having a first end and a second end; a flared portion coupled to the first end of the body and extending radially outwardly from the body and away from the second end of the body when the stent is in the expanded condition; and a plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition, wherein the flared portion and the second free ends of the anchor members are configured to extend away from the second end of the body when the stent is in the collapsed condition; and/or
-
- the flared portion and the body are each formed of a plurality of struts that form cells having an area, the area of each cell of the body being greater than the area of each cell of the flared portion when the stent is in the expanded condition; and/or
- the flared portion and the body are each formed of a plurality of struts having a thickness, the thickness of the struts forming the flared portion being less than the thickness of the struts forming the body.
- According to a further embodiment of the disclosure a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical center body having a first end and a second end; a first plurality of anchor members each having a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition; and a second plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition, wherein the first and second plurality of anchor members are configured to extend toward the second end of the body when the stent is in the collapsed condition.
- According to still another embodiment of the disclosure, a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical center body having a first end and a second end; a first plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition; and a second plurality of anchor members each having a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition, wherein the first plurality of anchor members extend toward the first end of the body and the second plurality of anchor members extend toward the second end of the body when the stent is in the collapsed condition; and/or
-
- the second plurality of anchor members includes a first group of anchor members and a second group of anchor members, the first group being configured to engage a native posterior mitral valve leaflet and the second group being configured to engage a native anterior mitral valve leaflet when the stent is implanted in a native mitral valve annulus of a patient.
- According to yet another embodiment of the disclosure, a stent having an expanded condition and a collapsed condition comprises: a substantially cylindrical center body having a first end, a second end, and a longitudinal axis extending between the first end and the second end; a first plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition; and a second plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition, wherein the first plurality of anchor members extend away from the second end of the body and the second plurality of anchor members extend away from the first end of the body when the stent is in the collapsed condition; and/or
-
- a plurality of struts forming a first circumferential row of cells and a second circumferential row of cells, wherein each of the first plurality of anchor members is at least partially formed from one of the cells in the first circumferential row and each of the second plurality of anchor members is at least partially formed from one of the cells in the second circumferential row.
- According to yet a further embodiment of the disclosure, a prosthetic heart valve comprises: a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition, the stent being formed from wire and having a first series of hooks and a second series of hooks; and a cuff coupled to the stent, wherein, when the stent is in the expanded condition, each hook of the first series extends radially outwardly from the stent at the inflow end and each hook of the second series includes a first portion that extends radially outwardly from the stent at the outflow end and a second portion that extends toward the inflow end; and/or
-
- the cuff has a first substantially flat portion that spans across and is coupled to the first series of hooks.
- According to an even further embodiment of the disclosure, a prosthetic heart valve comprises: a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition, the stent being formed of a plurality of struts; a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets; and a commissure attachment feature attached to at least one of the plurality of struts and positioned between the inflow end and the outflow end when the stent is in the expanded condition; and/or
-
- the commissure attachment feature has a first end attached to at least one of the plurality of struts and a second free end extending toward the inflow end when the stent is in the expanded condition.
- It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.
Claims (20)
1. A prosthetic heart valve, comprising:
a stent having an inflow end, an outflow end, a center portion between the inflow end and the outflow end, a collapsed condition, and an expanded condition;
a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets;
a first annular sealing member coupled to the inflow end; and
a second annular sealing member coupled to the outflow end.
2. The prosthetic heart valve of claim 1 , wherein the first and second sealing members each have a diameter greater than a diameter of the stent when the stent is in the expanded condition.
3. The prosthetic heart valve of claim 2 , wherein the stent is substantially cylindrical in the expanded condition.
4. The prosthetic heart valve of claim 2 , wherein the first sealing member has a substantially planar configuration when the stent is in the expanded condition.
5. The prosthetic heart valve of claim 2 , wherein the inflow end and the outflow end of the stent each has a diameter greater than a diameter of the center portion of the stent when the stent is in the expanded condition.
6. The prosthetic heart valve of claim 2 , wherein the first sealing member is substantially nonplanar when the stent is in the expanded condition.
7. The prosthetic heart valve of claim 6 , wherein an outer perimeter of the first sealing member is closer to the outflow end than an inner perimeter of the first sealing member when the stent is in the expanded condition.
8. The prosthetic heart valve of claim 6 , wherein an outer perimeter of the second sealing member is closer to the inflow end than an inner perimeter of the second sealing member when the stent is in the expanded condition.
9. A stent having an expanded condition and a collapsed condition, comprising:
a substantially cylindrical body having a first end and a second end;
a flared portion coupled to the first end of the body and extending radially outwardly from the body and away from the second end of the body when the stent is in the expanded condition; and
a plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition,
wherein the flared portion and the second free ends of the anchor members are configured to extend away from the second end of the body when the stent is in the collapsed condition.
10. The stent of claim 9 , wherein the flared portion and the body are each formed of a plurality of struts that form cells having an area, the area of each cell of the body being greater than the area of each cell of the flared portion when the stent is in the expanded condition.
11. The stent of claim 9 , wherein the flared portion and the body are each formed of a plurality of struts having a thickness, the thickness of the struts forming the flared portion being less than the thickness of the struts forming the body.
12. A stent having an expanded condition and a collapsed condition, comprising:
a substantially cylindrical center body having a first end and a second end;
a first plurality of anchor members each having a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition; and
a second plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition,
wherein the first and second plurality of anchor members are configured to extend toward the second end of the body when the stent is in the collapsed condition.
13. A stent having an expanded condition and a collapsed condition, comprising:
a substantially cylindrical center body having a first end and a second end;
a first plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and toward the first end of the body when the stent is in the expanded condition; and
a second plurality of anchor members each having a first end coupled to the first end of the body and a second free end extending radially outwardly from the body and toward the second end of the body when the stent is in the expanded condition,
wherein the first plurality of anchor members extend toward the first end of the body and the second plurality of anchor members extend toward the second end of the body when the stent is in the collapsed condition.
14. The stent of claim 13 , wherein the second plurality of anchor members includes a first group of anchor members and a second group of anchor members, the first group being configured to engage a native posterior mitral valve leaflet and the second group being configured to engage a native anterior mitral valve leaflet when the stent is implanted in a native mitral valve annulus of a patient.
15. A stent having an expanded condition and a collapsed condition, comprising:
a substantially cylindrical center body having a first end, a second end, and a longitudinal axis extending between the first end and the second end;
a first plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition; and
a second plurality of anchor members each having a first end coupled to the body and a second free end extending radially outwardly from the body and substantially perpendicular to the longitudinal axis of the body when the stent is in the expanded condition,
wherein the first plurality of anchor members extend away from the second end of the body and the second plurality of anchor members extend away from the first end of the body when the stent is in the collapsed condition.
16. The stent of claim 15 , further comprising:
a plurality of struts forming a first circumferential row of cells and a second circumferential row of cells,
wherein each of the first plurality of anchor members is at least partially formed from one of the cells in the first circumferential row and each of the second plurality of anchor members is at least partially formed from one of the cells in the second circumferential row.
17. A prosthetic heart valve, comprising:
a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition, the stent being formed from wire and having a first series of hooks and a second series of hooks; and
a cuff coupled to the stent,
wherein, when the stent is in the expanded condition, each hook of the first series extends radially outwardly from the stent at the inflow end and each hook of the second series includes a first portion that extends radially outwardly from the stent at the outflow end and a second portion that extends toward the inflow end.
18. The prosthetic heart valve of claim 17 , wherein the cuff has a first substantially flat portion that spans across and is coupled to the first series of hooks.
19. A prosthetic heart valve, comprising:
a stent having an inflow end, an outflow end, a collapsed condition, and an expanded condition, the stent being formed of a plurality of struts;
a collapsible and expandable valve assembly disposed within the stent and having a plurality of leaflets; and
a commissure attachment feature attached to at least one of the plurality of struts and positioned between the inflow end and the outflow end when the stent is in the expanded condition.
20. The prosthetic heart valve of claim 19 , wherein the commissure attachment feature has a first end attached to at least one of the plurality of struts and a second free end extending toward the inflow end when the stent is in the expanded condition.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/662,464 US20150272737A1 (en) | 2014-03-26 | 2015-03-19 | Transcatheter mitral valve stent frames |
US16/391,414 US11246706B2 (en) | 2014-03-26 | 2019-04-23 | Transcatheter mitral valve stent frames |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461970443P | 2014-03-26 | 2014-03-26 | |
US14/662,464 US20150272737A1 (en) | 2014-03-26 | 2015-03-19 | Transcatheter mitral valve stent frames |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/391,414 Division US11246706B2 (en) | 2014-03-26 | 2019-04-23 | Transcatheter mitral valve stent frames |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150272737A1 true US20150272737A1 (en) | 2015-10-01 |
Family
ID=52823806
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/662,464 Abandoned US20150272737A1 (en) | 2014-03-26 | 2015-03-19 | Transcatheter mitral valve stent frames |
US16/391,414 Active 2035-06-14 US11246706B2 (en) | 2014-03-26 | 2019-04-23 | Transcatheter mitral valve stent frames |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/391,414 Active 2035-06-14 US11246706B2 (en) | 2014-03-26 | 2019-04-23 | Transcatheter mitral valve stent frames |
Country Status (7)
Country | Link |
---|---|
US (2) | US20150272737A1 (en) |
EP (1) | EP3122289A1 (en) |
JP (1) | JP6526043B2 (en) |
AU (1) | AU2015236516A1 (en) |
CA (1) | CA2941398C (en) |
CR (1) | CR20160424A (en) |
WO (1) | WO2015148241A1 (en) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9295552B2 (en) | 2011-10-19 | 2016-03-29 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US20160095704A1 (en) * | 2010-01-20 | 2016-04-07 | Micro Interventional Devices, Inc. | Systems and Methods for Affixing A Prosthetic to Tissue |
US9421098B2 (en) | 2010-12-23 | 2016-08-23 | Twelve, Inc. | System for mitral valve repair and replacement |
US9572662B2 (en) | 2011-06-21 | 2017-02-21 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
WO2017196912A1 (en) * | 2016-05-13 | 2017-11-16 | St. Jude Medical, Cardiology Division, Inc. | Heart valve with stent having varying cell densities |
US20180021129A1 (en) * | 2016-07-21 | 2018-01-25 | Edwards Lifesciences Corporation | Replacement heart valve prosthesis |
US9901443B2 (en) | 2011-10-19 | 2018-02-27 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
USD815744S1 (en) | 2016-04-28 | 2018-04-17 | Edwards Lifesciences Cardiaq Llc | Valve frame for a delivery system |
US9974669B2 (en) | 2005-11-10 | 2018-05-22 | Edwards Lifesciences Cardiaq Llc | Percutaneous heart valve |
US10004599B2 (en) | 2014-02-21 | 2018-06-26 | Edwards Lifesciences Cardiaq Llc | Prosthesis, delivery device and methods of use |
US10010414B2 (en) | 2014-06-06 | 2018-07-03 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US20180206985A1 (en) * | 2017-01-23 | 2018-07-26 | Spencer NOE | Replacement mitral valves |
US10052201B2 (en) | 2016-09-21 | 2018-08-21 | Peijia Medical Co., Ltd. | Valved stent for mitral and tricuspid heart valve replacement |
CN108495602A (en) * | 2016-01-27 | 2018-09-04 | 美敦力公司 | System for repositioning the valve assemblies disposed completely |
US10092400B2 (en) | 2015-06-23 | 2018-10-09 | Edwards Lifesciences Cardiaq Llc | Systems and methods for anchoring and sealing a prosthetic heart valve |
US10111747B2 (en) | 2013-05-20 | 2018-10-30 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
US10117744B2 (en) | 2015-08-26 | 2018-11-06 | Edwards Lifesciences Cardiaq Llc | Replacement heart valves and methods of delivery |
US10149756B2 (en) | 2008-09-29 | 2018-12-11 | Edwards Lifesciences Cardiaq Llc | Heart valve |
US10179044B2 (en) | 2014-05-19 | 2019-01-15 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve |
WO2019028264A1 (en) * | 2017-08-03 | 2019-02-07 | The Regents Of The University Of California | Atrial cage for placement, securing and anchoring of atrioventricular valves |
US10226335B2 (en) | 2015-06-22 | 2019-03-12 | Edwards Lifesciences Cardiaq Llc | Actively controllable heart valve implant and method of controlling same |
US10238490B2 (en) | 2015-08-21 | 2019-03-26 | Twelve, Inc. | Implant heart valve devices, mitral valve repair devices and associated systems and methods |
US10265172B2 (en) | 2016-04-29 | 2019-04-23 | Medtronic Vascular, Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
US10350066B2 (en) | 2015-08-28 | 2019-07-16 | Edwards Lifesciences Cardiaq Llc | Steerable delivery system for replacement mitral valve and methods of use |
US10376363B2 (en) | 2015-04-30 | 2019-08-13 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve, delivery system for replacement mitral valve and methods of use |
US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
US10441412B2 (en) | 2009-04-15 | 2019-10-15 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US10441416B2 (en) | 2015-04-21 | 2019-10-15 | Edwards Lifesciences Corporation | Percutaneous mitral valve replacement device |
US20190336287A1 (en) * | 2011-03-21 | 2019-11-07 | Cephea Valve Technologies, Inc. | Disk-based Valve Apparatus And Method For The Treatment Of Valve Dysfunction |
US10485660B2 (en) | 2010-06-21 | 2019-11-26 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve |
US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
US10575951B2 (en) | 2015-08-26 | 2020-03-03 | Edwards Lifesciences Cardiaq Llc | Delivery device and methods of use for transapical delivery of replacement mitral valve |
US10583000B2 (en) | 2013-03-14 | 2020-03-10 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US10639143B2 (en) | 2016-08-26 | 2020-05-05 | Edwards Lifesciences Corporation | Multi-portion replacement heart valve prosthesis |
US10646340B2 (en) | 2016-08-19 | 2020-05-12 | Edwards Lifesciences Corporation | Steerable delivery system for replacement mitral valve |
US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
US10702380B2 (en) | 2011-10-19 | 2020-07-07 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
US10716664B2 (en) | 2013-03-14 | 2020-07-21 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
WO2020167827A1 (en) * | 2019-02-11 | 2020-08-20 | W. L. Gore & Associates, Inc. | Universal heart valve device |
US10758348B2 (en) | 2016-11-02 | 2020-09-01 | Edwards Lifesciences Corporation | Supra and sub-annular mitral valve delivery system |
US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
US10813757B2 (en) | 2017-07-06 | 2020-10-27 | Edwards Lifesciences Corporation | Steerable rail delivery system |
US10912644B2 (en) | 2018-10-05 | 2021-02-09 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
US10952846B2 (en) * | 2008-05-01 | 2021-03-23 | Edwards Lifesciences Corporation | Method of replacing mitral valve |
US11051934B2 (en) | 2018-02-28 | 2021-07-06 | Edwards Lifesciences Corporation | Prosthetic mitral valve with improved anchors and seal |
US20210236276A1 (en) * | 2020-01-31 | 2021-08-05 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
US11090158B2 (en) | 2017-01-23 | 2021-08-17 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US11241307B2 (en) | 2016-10-13 | 2022-02-08 | Boston Scientific Scimed, Inc. | Replacement heart valve with diaphragm |
WO2022156335A1 (en) * | 2021-01-20 | 2022-07-28 | 上海纽脉医疗科技股份有限公司 | Interventional artificial heart valve and medical apparatus |
US20220265421A1 (en) * | 2021-02-19 | 2022-08-25 | Johnson Consulting Llc | Anchoring frame device for an artificial valve and related systems and method |
US11471282B2 (en) | 2019-03-19 | 2022-10-18 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
USD977101S1 (en) | 2017-02-01 | 2023-01-31 | Edwards Lifesciences Corporation | Stent |
US11596514B2 (en) | 2016-02-05 | 2023-03-07 | Edwards Lifesciences Corporation | Devices and systems for docking a heart valve |
US11617646B2 (en) | 2015-05-14 | 2023-04-04 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
US11684474B2 (en) | 2018-01-25 | 2023-06-27 | Edwards Lifesciences Corporation | Delivery system for aided replacement valve recapture and repositioning post-deployment |
US11833034B2 (en) | 2016-01-13 | 2023-12-05 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
US11938314B2 (en) | 2016-02-22 | 2024-03-26 | The Charles Stark Draper Laboratory, Inc. | Method of manufacturing an implantable neural electrode interface platform |
US11951001B2 (en) | 2020-07-08 | 2024-04-09 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grapsing intralumenal tissue and methods of delivery |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10849755B2 (en) | 2012-09-14 | 2020-12-01 | Boston Scientific Scimed, Inc. | Mitral valve inversion prostheses |
WO2016154172A2 (en) * | 2015-03-24 | 2016-09-29 | St. Jude Medical, Cardiology Division, Inc. | Mitral heart valve replacement |
JP2019503813A (en) * | 2016-02-04 | 2019-02-14 | ミリピード, インコーポレイテッドMillipede, Inc. | Mitral valve reversal prosthesis |
US10561495B2 (en) | 2017-01-24 | 2020-02-18 | 4C Medical Technologies, Inc. | Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve |
US10842619B2 (en) * | 2017-05-12 | 2020-11-24 | Edwards Lifesciences Corporation | Prosthetic heart valve docking assembly |
WO2019195860A2 (en) | 2018-04-04 | 2019-10-10 | Vdyne, Llc | Devices and methods for anchoring transcatheter heart valve |
US11857441B2 (en) | 2018-09-04 | 2024-01-02 | 4C Medical Technologies, Inc. | Stent loading device |
US11278437B2 (en) | 2018-12-08 | 2022-03-22 | Vdyne, Inc. | Compression capable annular frames for side delivery of transcatheter heart valve replacement |
US10321995B1 (en) | 2018-09-20 | 2019-06-18 | Vdyne, Llc | Orthogonally delivered transcatheter heart valve replacement |
US11344413B2 (en) | 2018-09-20 | 2022-05-31 | Vdyne, Inc. | Transcatheter deliverable prosthetic heart valves and methods of delivery |
US11071627B2 (en) | 2018-10-18 | 2021-07-27 | Vdyne, Inc. | Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis |
US10595994B1 (en) | 2018-09-20 | 2020-03-24 | Vdyne, Llc | Side-delivered transcatheter heart valve replacement |
US11109969B2 (en) | 2018-10-22 | 2021-09-07 | Vdyne, Inc. | Guidewire delivery of transcatheter heart valve |
US11253359B2 (en) | 2018-12-20 | 2022-02-22 | Vdyne, Inc. | Proximal tab for side-delivered transcatheter heart valves and methods of delivery |
US11273032B2 (en) | 2019-01-26 | 2022-03-15 | Vdyne, Inc. | Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis |
US11185409B2 (en) | 2019-01-26 | 2021-11-30 | Vdyne, Inc. | Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis |
CN113543750A (en) | 2019-03-05 | 2021-10-22 | 维迪内股份有限公司 | Tricuspid valve regurgitation control apparatus for orthogonal transcatheter heart valve prosthesis |
US11076956B2 (en) | 2019-03-14 | 2021-08-03 | Vdyne, Inc. | Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis |
US11173027B2 (en) | 2019-03-14 | 2021-11-16 | Vdyne, Inc. | Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same |
CN114072106A (en) | 2019-05-04 | 2022-02-18 | 维迪内股份有限公司 | Cinching device and method for deploying a laterally delivered prosthetic heart valve in a native annulus |
JP2022544707A (en) | 2019-08-20 | 2022-10-20 | ブイダイン,インコーポレイテッド | Devices and methods for delivery and retrieval of laterally deliverable transcatheter valve prostheses |
WO2021040996A1 (en) | 2019-08-26 | 2021-03-04 | Vdyne, Inc. | Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same |
US11234813B2 (en) | 2020-01-17 | 2022-02-01 | Vdyne, Inc. | Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090216310A1 (en) * | 2008-02-26 | 2009-08-27 | Helmut Straubinger | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US20090292350A1 (en) * | 2008-01-24 | 2009-11-26 | Medtronic, Inc. | Stents for Prosthetic Heart Valves |
US20100082094A1 (en) * | 2008-09-29 | 2010-04-01 | Arshad Quadri | Heart valve |
US20100298931A1 (en) * | 2009-04-15 | 2010-11-25 | Arshad Quadri | Vascular implant and delivery system |
US20110208290A1 (en) * | 2008-02-26 | 2011-08-25 | Helmut Straubinger | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US20120271398A1 (en) * | 2009-11-02 | 2012-10-25 | Symetis Sa | Aortic bioprosthesis and systems for delivery thereof |
US20140277411A1 (en) * | 2011-09-12 | 2014-09-18 | Highlife Sas | Transcatheter valve prosthesis |
US20140343669A1 (en) * | 2013-04-04 | 2014-11-20 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
Family Cites Families (267)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4491986A (en) | 1976-05-12 | 1985-01-08 | Shlomo Gabbay | Heart valve |
US4275469A (en) | 1979-12-13 | 1981-06-30 | Shelhigh Inc. | Prosthetic heart valve |
US4759758A (en) | 1984-12-07 | 1988-07-26 | Shlomo Gabbay | Prosthetic heart valve |
DE3640745A1 (en) | 1985-11-30 | 1987-06-04 | Ernst Peter Prof Dr M Strecker | Catheter for producing or extending connections to or between body cavities |
US4878906A (en) | 1986-03-25 | 1989-11-07 | Servetus Partnership | Endoprosthesis for repairing a damaged vessel |
US4994077A (en) | 1989-04-21 | 1991-02-19 | Dobben Richard L | Artificial heart valve for implantation in a blood vessel |
DK124690D0 (en) | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US5411552A (en) | 1990-05-18 | 1995-05-02 | Andersen; Henning R. | Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis |
US5843167A (en) | 1993-04-22 | 1998-12-01 | C. R. Bard, Inc. | Method and apparatus for recapture of hooked endoprosthesis |
US5480423A (en) | 1993-05-20 | 1996-01-02 | Boston Scientific Corporation | Prosthesis delivery |
US5713950A (en) | 1993-11-01 | 1998-02-03 | Cox; James L. | Method of replacing heart valves using flexible tubes |
EP0657147B1 (en) | 1993-11-04 | 1999-08-04 | C.R. Bard, Inc. | Non-migrating vascular prosthesis |
GB9522332D0 (en) | 1995-11-01 | 1996-01-03 | Biocompatibles Ltd | Braided stent |
DE69526857T2 (en) | 1995-11-27 | 2003-01-02 | Schneider Europ Gmbh Buelach | Stent for use in one pass |
US7238197B2 (en) | 2000-05-30 | 2007-07-03 | Devax, Inc. | Endoprosthesis deployment system for treating vascular bifurcations |
US5855601A (en) | 1996-06-21 | 1999-01-05 | The Trustees Of Columbia University In The City Of New York | Artificial heart valve and method and device for implanting the same |
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
EP1656892A3 (en) | 1997-01-24 | 2006-05-31 | Paragon Intellectual Properties, LLC | Expandable device comprising bistable unit cells |
US5961549A (en) | 1997-04-03 | 1999-10-05 | Baxter International Inc. | Multi-leaflet bioprosthetic heart valve |
US6045576A (en) | 1997-09-16 | 2000-04-04 | Baxter International Inc. | Sewing ring having increased annular coaptation |
US5954766A (en) | 1997-09-16 | 1999-09-21 | Zadno-Azizi; Gholam-Reza | Body fluid flow control device |
US5938697A (en) | 1998-03-04 | 1999-08-17 | Scimed Life Systems, Inc. | Stent having variable properties |
US5935163A (en) | 1998-03-31 | 1999-08-10 | Shelhigh, Inc. | Natural tissue heart valve prosthesis |
US7452371B2 (en) | 1999-06-02 | 2008-11-18 | Cook Incorporated | Implantable vascular device |
US6254564B1 (en) | 1998-09-10 | 2001-07-03 | Percardia, Inc. | Left ventricular conduit with blood vessel graft |
US6214036B1 (en) | 1998-11-09 | 2001-04-10 | Cordis Corporation | Stent which is easily recaptured and repositioned within the body |
DE19857887B4 (en) | 1998-12-15 | 2005-05-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anchoring support for a heart valve prosthesis |
US6558414B2 (en) | 1999-02-02 | 2003-05-06 | Impra, Inc. | Partial encapsulation of stents using strips and bands |
US6090140A (en) | 1999-02-17 | 2000-07-18 | Shelhigh, Inc. | Extra-anatomic heart valve apparatus |
US6264691B1 (en) | 1999-04-23 | 2001-07-24 | Shlomo Gabbay | Apparatus and method for supporting a heart valve |
EP1229865B1 (en) | 1999-09-10 | 2010-11-17 | Cook Incorporated | Endovascular treatment for chronic venous insufficiency |
US6440164B1 (en) | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US20070043435A1 (en) | 1999-11-17 | 2007-02-22 | Jacques Seguin | Non-cylindrical prosthetic valve system for transluminal delivery |
US8579966B2 (en) | 1999-11-17 | 2013-11-12 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
FR2800984B1 (en) | 1999-11-17 | 2001-12-14 | Jacques Seguin | DEVICE FOR REPLACING A HEART VALVE PERCUTANEOUSLY |
FR2815844B1 (en) | 2000-10-31 | 2003-01-17 | Jacques Seguin | TUBULAR SUPPORT FOR THE PERCUTANEOUS POSITIONING OF A REPLACEMENT HEART VALVE |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
US8016877B2 (en) | 1999-11-17 | 2011-09-13 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US7195641B2 (en) | 1999-11-19 | 2007-03-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US6458153B1 (en) | 1999-12-31 | 2002-10-01 | Abps Venture One, Ltd. | Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof |
PL211860B1 (en) | 2000-01-31 | 2012-07-31 | Cook Biotech Inc | Valve stent system |
DE60127530T2 (en) | 2000-02-03 | 2007-12-13 | Cook Inc., Bloomington | IMPLANTABLE VASCULAR DEVICE |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US6610088B1 (en) | 2000-05-03 | 2003-08-26 | Shlomo Gabbay | Biologically covered heart valve prosthesis |
US6368348B1 (en) | 2000-05-15 | 2002-04-09 | Shlomo Gabbay | Annuloplasty prosthesis for supporting an annulus of a heart valve |
US6419695B1 (en) | 2000-05-22 | 2002-07-16 | Shlomo Gabbay | Cardiac prosthesis for helping improve operation of a heart valve |
US6869444B2 (en) | 2000-05-22 | 2005-03-22 | Shlomo Gabbay | Low invasive implantable cardiac prosthesis and method for helping improve operation of a heart valve |
US8366769B2 (en) | 2000-06-01 | 2013-02-05 | Edwards Lifesciences Corporation | Low-profile, pivotable heart valve sewing ring |
US7510572B2 (en) | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
WO2002022054A1 (en) | 2000-09-12 | 2002-03-21 | Gabbay S | Valvular prosthesis and method of using same |
US6685625B2 (en) | 2000-09-26 | 2004-02-03 | Shlomo Gabbay | Curved implantable sheath and method of making same |
US6783556B1 (en) | 2000-09-26 | 2004-08-31 | Shlomo Gabbay | System and method for making a calotte-shaped implantable sheath |
US20020036220A1 (en) | 2000-09-26 | 2002-03-28 | Shlomo Gabbay | Curved implantable sheath and method of making same |
US6517576B2 (en) | 2000-12-11 | 2003-02-11 | Shlomo Gabbay | Implantable patch prosthesis having one or more cusps for improved competency |
US20040093075A1 (en) | 2000-12-15 | 2004-05-13 | Titus Kuehne | Stent with valve and method of use thereof |
US6716244B2 (en) | 2000-12-20 | 2004-04-06 | Carbomedics, Inc. | Sewing cuff assembly for heart valves |
US6468660B2 (en) | 2000-12-29 | 2002-10-22 | St. Jude Medical, Inc. | Biocompatible adhesives |
US6623518B2 (en) | 2001-02-26 | 2003-09-23 | Ev3 Peripheral, Inc. | Implant delivery system with interlock |
US7556646B2 (en) | 2001-09-13 | 2009-07-07 | Edwards Lifesciences Corporation | Methods and apparatuses for deploying minimally-invasive heart valves |
DE10121210B4 (en) | 2001-04-30 | 2005-11-17 | Universitätsklinikum Freiburg | Anchoring element for the intraluminal anchoring of a heart valve replacement and method for its production |
FR2828091B1 (en) | 2001-07-31 | 2003-11-21 | Seguin Jacques | ASSEMBLY ALLOWING THE PLACEMENT OF A PROTHETIC VALVE IN A BODY DUCT |
US20080021552A1 (en) | 2001-10-09 | 2008-01-24 | Shlomo Gabbay | Apparatus To Facilitate Implantation |
US6893460B2 (en) | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
US6951573B1 (en) | 2001-12-22 | 2005-10-04 | Dilling Emery W | Prosthetic aortic valve |
DE10221076A1 (en) | 2002-05-11 | 2003-11-27 | Ruesch Willy Gmbh | stent |
US7137184B2 (en) | 2002-09-20 | 2006-11-21 | Edwards Lifesciences Corporation | Continuous heart valve support frame and method of manufacture |
US6814746B2 (en) | 2002-11-01 | 2004-11-09 | Ev3 Peripheral, Inc. | Implant delivery system with marker interlock |
FR2847800B1 (en) | 2002-11-28 | 2005-10-14 | Perouse Laboratoires | INTERCHANGEABLE PROTHETIC VALVE |
US20040111111A1 (en) | 2002-12-10 | 2004-06-10 | Scimed Life Systems, Inc. | Intravascular filter membrane with shape memory |
FR2850008A1 (en) | 2003-01-17 | 2004-07-23 | Daniel Roux | Vascular prosthesis has tube and collar for adapting to blood vessel ends of different diameters |
JP4473861B2 (en) | 2003-03-20 | 2010-06-02 | エイオアテック、インターナショナル、ピーエルシー | valve |
US8221492B2 (en) | 2003-04-24 | 2012-07-17 | Cook Medical Technologies | Artificial valve prosthesis with improved flow dynamics |
US7717952B2 (en) | 2003-04-24 | 2010-05-18 | Cook Incorporated | Artificial prostheses with preferred geometries |
US7201772B2 (en) | 2003-07-08 | 2007-04-10 | Ventor Technologies, Ltd. | Fluid flow prosthetic device |
US7160322B2 (en) | 2003-08-13 | 2007-01-09 | Shlomo Gabbay | Implantable cardiac prosthesis for mitigating prolapse of a heart valve |
US20060259137A1 (en) | 2003-10-06 | 2006-11-16 | Jason Artof | Minimally invasive valve replacement system |
US7261732B2 (en) | 2003-12-22 | 2007-08-28 | Henri Justino | Stent mounted valve |
US8343213B2 (en) | 2003-12-23 | 2013-01-01 | Sadra Medical, Inc. | Leaflet engagement elements and methods for use thereof |
US7824442B2 (en) | 2003-12-23 | 2010-11-02 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a heart valve |
US7748389B2 (en) | 2003-12-23 | 2010-07-06 | Sadra Medical, Inc. | Leaflet engagement elements and methods for use thereof |
US7959666B2 (en) | 2003-12-23 | 2011-06-14 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a heart valve |
ES2547693T5 (en) | 2003-12-23 | 2020-05-29 | Boston Scient Scimed Inc | Replaceable heart valve |
US8579962B2 (en) | 2003-12-23 | 2013-11-12 | Sadra Medical, Inc. | Methods and apparatus for performing valvuloplasty |
US8840663B2 (en) | 2003-12-23 | 2014-09-23 | Sadra Medical, Inc. | Repositionable heart valve method |
US7780725B2 (en) | 2004-06-16 | 2010-08-24 | Sadra Medical, Inc. | Everting heart valve |
US8603160B2 (en) | 2003-12-23 | 2013-12-10 | Sadra Medical, Inc. | Method of using a retrievable heart valve anchor with a sheath |
US7445631B2 (en) | 2003-12-23 | 2008-11-04 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US20050137686A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical, A Delaware Corporation | Externally expandable heart valve anchor and method |
US8182528B2 (en) | 2003-12-23 | 2012-05-22 | Sadra Medical, Inc. | Locking heart valve anchor |
US8828078B2 (en) | 2003-12-23 | 2014-09-09 | Sadra Medical, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US9005273B2 (en) | 2003-12-23 | 2015-04-14 | Sadra Medical, Inc. | Assessing the location and performance of replacement heart valves |
US7311730B2 (en) | 2004-02-13 | 2007-12-25 | Shlomo Gabbay | Support apparatus and heart valve prosthesis for sutureless implantation |
US7247167B2 (en) | 2004-02-19 | 2007-07-24 | Shlomo Gabbay | Low profile heart valve prosthesis |
ITTO20040135A1 (en) | 2004-03-03 | 2004-06-03 | Sorin Biomedica Cardio Spa | CARDIAC VALVE PROSTHESIS |
US8979922B2 (en) | 2004-03-11 | 2015-03-17 | Percutaneous Cardiovascular Solutions Pty Limited | Percutaneous heart valve prosthesis |
JP2007529273A (en) | 2004-03-15 | 2007-10-25 | メドトロニック ヴァスキュラー インコーポレイテッド | Stent resistant to radial crush |
US7374573B2 (en) | 2004-05-03 | 2008-05-20 | Shlomo Gabbay | System and method for improving ventricular function |
US20050256566A1 (en) | 2004-05-03 | 2005-11-17 | Shlomo Gabbay | Apparatus and method for improving ventricular function |
ES2407684T3 (en) | 2004-05-05 | 2013-06-13 | Direct Flow Medical, Inc. | Heart valve without stent with support structure formed on site |
US20060122692A1 (en) | 2004-05-10 | 2006-06-08 | Ran Gilad | Stent valve and method of using same |
US7276078B2 (en) | 2004-06-30 | 2007-10-02 | Edwards Lifesciences Pvt | Paravalvular leak detection, sealing, and prevention |
US20060008497A1 (en) | 2004-07-09 | 2006-01-12 | Shlomo Gabbay | Implantable apparatus having improved biocompatibility and process of making the same |
FR2874812B1 (en) | 2004-09-07 | 2007-06-15 | Perouse Soc Par Actions Simpli | INTERCHANGEABLE PROTHETIC VALVE |
JP2008514345A (en) | 2004-10-02 | 2008-05-08 | クリストフ・ハンス・フーバー | Device for treating or replacing a heart valve or surrounding tissue without requiring full cardiopulmonary support |
US8562672B2 (en) | 2004-11-19 | 2013-10-22 | Medtronic, Inc. | Apparatus for treatment of cardiac valves and method of its manufacture |
WO2006055982A2 (en) | 2004-11-22 | 2006-05-26 | Avvrx | Ring-shaped valve prosthesis attachment device |
EP1848368A1 (en) | 2004-12-20 | 2007-10-31 | Cook Incorporated | Intraluminal support frame and medical devices including the support frame |
CA2592773C (en) | 2005-01-05 | 2011-04-26 | The Cleveland Clinic Foundation | Method for fixing tissue |
ITTO20050074A1 (en) | 2005-02-10 | 2006-08-11 | Sorin Biomedica Cardio Srl | CARDIAC VALVE PROSTHESIS |
SE531468C2 (en) | 2005-04-21 | 2009-04-14 | Edwards Lifesciences Ag | An apparatus for controlling blood flow |
EP1885286B1 (en) | 2005-05-12 | 2017-09-20 | Covidien LP | Implant delivery system with interlocked rx port orientation |
US7914569B2 (en) | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
CA2609022C (en) | 2005-05-20 | 2010-07-20 | The Cleveland Clinic Foundation | Apparatus and methods for repairing the function of a diseased valve and method for making same |
US10092429B2 (en) | 2005-08-22 | 2018-10-09 | Incept, Llc | Flared stents and apparatus and methods for delivering them |
CN101180010B (en) | 2005-05-24 | 2010-12-01 | 爱德华兹生命科学公司 | Rapid deployment prosthetic heart valve |
CN101247773B (en) | 2005-05-27 | 2010-12-15 | 心叶科技公司 | Stentless support structure |
US8663312B2 (en) | 2005-05-27 | 2014-03-04 | Hlt, Inc. | Intravascular cuff |
WO2007013999A2 (en) | 2005-07-21 | 2007-02-01 | Florida International University | Collapsible heart valve with polymer leaflets |
US8790396B2 (en) | 2005-07-27 | 2014-07-29 | Medtronic 3F Therapeutics, Inc. | Methods and systems for cardiac valve delivery |
EP1906873A2 (en) | 2005-07-27 | 2008-04-09 | Georgia Tech Research Corporation | Implantable prosthetic vascular valve |
US20070067029A1 (en) | 2005-09-16 | 2007-03-22 | Shlomo Gabbay | Support apparatus to facilitate implantation of cardiac prosthesis |
US8092525B2 (en) | 2005-10-26 | 2012-01-10 | Cardiosolutions, Inc. | Heart valve implant |
DE102005052628B4 (en) | 2005-11-04 | 2014-06-05 | Jenavalve Technology Inc. | Self-expanding, flexible wire mesh with integrated valvular prosthesis for the transvascular heart valve replacement and a system with such a device and a delivery catheter |
US8764820B2 (en) | 2005-11-16 | 2014-07-01 | Edwards Lifesciences Corporation | Transapical heart valve delivery system and method |
EP1948088A2 (en) | 2005-11-18 | 2008-07-30 | Innovia LLC | Trileaflet heart valve |
US20070142907A1 (en) | 2005-12-16 | 2007-06-21 | Micardia Corporation | Adjustable prosthetic valve implant |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
MX2008008068A (en) | 2005-12-22 | 2008-09-10 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery. |
EP1988851A2 (en) | 2006-02-14 | 2008-11-12 | Sadra Medical, Inc. | Systems and methods for delivering a medical implant |
EP2583640B1 (en) | 2006-02-16 | 2022-06-22 | Venus MedTech (HangZhou), Inc. | Minimally invasive replacement heart valve |
US8075615B2 (en) | 2006-03-28 | 2011-12-13 | Medtronic, Inc. | Prosthetic cardiac valve formed from pericardium material and methods of making same |
US7524331B2 (en) | 2006-04-06 | 2009-04-28 | Medtronic Vascular, Inc. | Catheter delivered valve having a barrier to provide an enhanced seal |
US20070244545A1 (en) | 2006-04-14 | 2007-10-18 | Medtronic Vascular, Inc. | Prosthetic Conduit With Radiopaque Symmetry Indicators |
EP2478872B1 (en) | 2006-05-30 | 2018-07-04 | Cook Medical Technologies LLC | Artificial valve prosthesis |
US20080097595A1 (en) | 2006-08-22 | 2008-04-24 | Shlomo Gabbay | Intraventricular cardiac prosthesis |
US8348996B2 (en) | 2006-09-19 | 2013-01-08 | Medtronic Ventor Technologies Ltd. | Valve prosthesis implantation techniques |
US8834564B2 (en) * | 2006-09-19 | 2014-09-16 | Medtronic, Inc. | Sinus-engaging valve fixation member |
US7534261B2 (en) | 2006-10-02 | 2009-05-19 | Edwards Lifesciences Corporation | Sutureless heart valve attachment |
SE530568C2 (en) | 2006-11-13 | 2008-07-08 | Medtentia Ab | Medical device for improving function of heart valve, has flange unit connected to loop-shaped support and provided to be arranged against annulus when loop shaped support abut heart valve |
US8747459B2 (en) | 2006-12-06 | 2014-06-10 | Medtronic Corevalve Llc | System and method for transapical delivery of an annulus anchored self-expanding valve |
FR2909857B1 (en) | 2006-12-14 | 2009-03-06 | Perouse Soc Par Actions Simpli | Endovalve. |
US8236045B2 (en) | 2006-12-22 | 2012-08-07 | Edwards Lifesciences Corporation | Implantable prosthetic valve assembly and method of making the same |
WO2008092101A2 (en) | 2007-01-26 | 2008-07-31 | 3F Therapeutics, Inc. | Methods and systems for reducing paravalvular leakage in heart valves |
WO2008101193A2 (en) | 2007-02-16 | 2008-08-21 | Emory University | Apparatus and methods for treating the aorta |
EP2129333B1 (en) | 2007-02-16 | 2019-04-03 | Medtronic, Inc | Replacement prosthetic heart valves |
US20080208327A1 (en) * | 2007-02-27 | 2008-08-28 | Rowe Stanton J | Method and apparatus for replacing a prosthetic valve |
WO2008125153A1 (en) * | 2007-04-13 | 2008-10-23 | Jenavalve Technology Inc. | Medical device for treating a heart valve insufficiency or stenosis |
AU2008260444B2 (en) | 2007-06-04 | 2014-09-11 | St. Jude Medical, Inc. | Prosthetic heart valves |
BRPI0812890A2 (en) | 2007-06-08 | 2017-05-23 | St Jude Medical | apparatus for providing instrumentation to a patient's circulatory system; and apparatus for closing an opening through a wall of a patient's circulatory system. |
AU2008269018B2 (en) | 2007-06-26 | 2014-07-31 | St. Jude Medical, Inc. | Apparatus and methods for implanting collapsible/expandable prosthetic heart valves |
EP2484311B1 (en) | 2007-08-24 | 2015-05-06 | St. Jude Medical, Inc. | Prosthetic aortic heart valve |
ES2571740T3 (en) | 2007-09-26 | 2016-05-26 | St Jude Medical | Collapsible prosthetic heart valves |
US8454686B2 (en) | 2007-09-28 | 2013-06-04 | St. Jude Medical, Inc. | Two-stage collapsible/expandable prosthetic heart valves and anchoring systems |
WO2009045334A1 (en) | 2007-09-28 | 2009-04-09 | St. Jude Medical, Inc. | Collapsible/expandable prosthetic heart valves with native calcified leaflet retention features |
US9532868B2 (en) | 2007-09-28 | 2017-01-03 | St. Jude Medical, Inc. | Collapsible-expandable prosthetic heart valves with structures for clamping native tissue |
US20090138079A1 (en) | 2007-10-10 | 2009-05-28 | Vector Technologies Ltd. | Prosthetic heart valve for transfemoral delivery |
US9848981B2 (en) | 2007-10-12 | 2017-12-26 | Mayo Foundation For Medical Education And Research | Expandable valve prosthesis with sealing mechanism |
WO2009061389A2 (en) | 2007-11-05 | 2009-05-14 | St. Jude Medical, Inc. | Collapsible/expandable prosthetic heart valves with non-expanding stent posts and retrieval features |
US20080114452A1 (en) | 2007-11-14 | 2008-05-15 | Shlomo Gabbay | Prosthesis exhibiting post-implantation size change |
AU2009205739B2 (en) | 2008-01-16 | 2014-09-25 | St. Jude Medical, Inc. | Delivery and retrieval systems for collapsible/expandable prosthetic heart valves |
JP5687070B2 (en) | 2008-01-24 | 2015-03-18 | メドトロニック,インコーポレイテッド | Stent for prosthetic heart valve |
CA2715448C (en) | 2008-02-25 | 2017-06-13 | Medtronic Vascular Inc. | Infundibular reducer devices |
EP3005984A1 (en) | 2008-02-28 | 2016-04-13 | Medtronic Inc. | Prosthetic heart valve systems |
US8313525B2 (en) | 2008-03-18 | 2012-11-20 | Medtronic Ventor Technologies, Ltd. | Valve suturing and implantation procedures |
JP5685183B2 (en) * | 2008-04-23 | 2015-03-18 | メドトロニック,インコーポレイテッド | Heart valve device with stent |
US8323336B2 (en) | 2008-04-23 | 2012-12-04 | Medtronic, Inc. | Prosthetic heart valve devices and methods of valve replacement |
US20090276027A1 (en) | 2008-05-01 | 2009-11-05 | Medtronic Vasscular, Inc. | Stent Graft Delivery System and Method of Use |
DK3476368T3 (en) | 2008-06-06 | 2020-03-02 | Edwards Lifesciences Corp | Low profile transcatheter heart valve |
US8323335B2 (en) | 2008-06-20 | 2012-12-04 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves and methods for using |
ES2792354T3 (en) | 2008-07-15 | 2020-11-11 | St Jude Medical Llc | Foldable and re-expandable prosthetic heart valves, with axial anchoring, for various disease states |
ES2570592T3 (en) | 2008-07-15 | 2016-05-19 | St Jude Medical | Collapsible and re-expandable prosthetic heart valve sleeve designs and complementary technological applications |
DE202008009610U1 (en) | 2008-07-17 | 2008-12-11 | Nvt Ag | Prosthetic heart valve system |
EP2334261B1 (en) | 2008-07-21 | 2021-01-13 | Jenesis Surgical, LLC | Endoluminal support apparatus and method of fabricating it |
US8137398B2 (en) | 2008-10-13 | 2012-03-20 | Medtronic Ventor Technologies Ltd | Prosthetic valve having tapered tip when compressed for delivery |
US8230717B2 (en) | 2008-12-18 | 2012-07-31 | Ethicon, Inc. | Paravalvular leak test apparatus and method |
US8308798B2 (en) | 2008-12-19 | 2012-11-13 | Edwards Lifesciences Corporation | Quick-connect prosthetic heart valve and methods |
US8834563B2 (en) | 2008-12-23 | 2014-09-16 | Sorin Group Italia S.R.L. | Expandable prosthetic valve having anchoring appendages |
ES2644852T3 (en) | 2009-02-20 | 2017-11-30 | St. Jude Medical, Inc. | Devices and methods for folding prosthetic heart valves |
US20100217382A1 (en) | 2009-02-25 | 2010-08-26 | Edwards Lifesciences | Mitral valve replacement with atrial anchoring |
WO2010098857A1 (en) | 2009-02-27 | 2010-09-02 | St. Jude Medical, Inc. | Stent features for collapsible prosthetic heart valves |
US8021420B2 (en) | 2009-03-12 | 2011-09-20 | Medtronic Vascular, Inc. | Prosthetic valve delivery system |
US8052741B2 (en) | 2009-03-23 | 2011-11-08 | Medtronic Vascular, Inc. | Branch vessel prosthesis with a roll-up sealing assembly |
US9173760B2 (en) * | 2009-04-03 | 2015-11-03 | Metamodix, Inc. | Delivery devices and methods for gastrointestinal implants |
US9636204B2 (en) * | 2009-04-16 | 2017-05-02 | Cvdevices, Llc | Deflection devices, systems and methods for the prevention of stroke |
US8075611B2 (en) | 2009-06-02 | 2011-12-13 | Medtronic, Inc. | Stented prosthetic heart valves |
US8348998B2 (en) | 2009-06-26 | 2013-01-08 | Edwards Lifesciences Corporation | Unitary quick connect prosthetic heart valve and deployment system and methods |
US8845722B2 (en) | 2009-08-03 | 2014-09-30 | Shlomo Gabbay | Heart valve prosthesis and method of implantation thereof |
US8801706B2 (en) | 2009-08-27 | 2014-08-12 | Medtronic, Inc. | Paravalvular leak closure devices and methods |
EP2480167B1 (en) | 2009-09-21 | 2017-08-16 | Medtronic Inc. | Stented transcatheter prosthetic heart valve delivery system |
US20190060070A1 (en) * | 2009-10-06 | 2019-02-28 | Adam Groothuis | Systems and methods for treating lumenal valves |
AU2010315030B2 (en) | 2009-11-05 | 2016-03-10 | The Trustees Of The University Of Pennsylvania | Valve prosthesis |
US8449599B2 (en) | 2009-12-04 | 2013-05-28 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
US20130190861A1 (en) * | 2012-01-23 | 2013-07-25 | Tendyne Holdings, Inc. | Prosthetic Valve for Replacing Mitral Valve |
US9226826B2 (en) | 2010-02-24 | 2016-01-05 | Medtronic, Inc. | Transcatheter valve structure and methods for valve delivery |
US9522062B2 (en) | 2010-02-24 | 2016-12-20 | Medtronic Ventor Technologies, Ltd. | Mitral prosthesis and methods for implantation |
US8652204B2 (en) | 2010-04-01 | 2014-02-18 | Medtronic, Inc. | Transcatheter valve with torsion spring fixation and related systems and methods |
WO2011133787A1 (en) | 2010-04-21 | 2011-10-27 | Medtronic Inc. | Prosthetic valve with sealing members and methods of use thereof |
US8568474B2 (en) | 2010-04-26 | 2013-10-29 | Medtronic, Inc. | Transcatheter prosthetic heart valve post-dilatation remodeling devices and methods |
US8408214B2 (en) | 2010-07-08 | 2013-04-02 | Benjamin Spenser | Method for implanting prosthetic valve |
US8992604B2 (en) * | 2010-07-21 | 2015-03-31 | Mitraltech Ltd. | Techniques for percutaneous mitral valve replacement and sealing |
US9763657B2 (en) * | 2010-07-21 | 2017-09-19 | Mitraltech Ltd. | Techniques for percutaneous mitral valve replacement and sealing |
CN106073946B (en) * | 2010-09-10 | 2022-01-04 | 西美蒂斯股份公司 | Valve replacement device, delivery device for a valve replacement device and method of producing a valve replacement device |
USD660433S1 (en) | 2010-09-20 | 2012-05-22 | St. Jude Medical, Inc. | Surgical stent assembly |
USD653342S1 (en) | 2010-09-20 | 2012-01-31 | St. Jude Medical, Inc. | Stent connections |
USD653341S1 (en) | 2010-09-20 | 2012-01-31 | St. Jude Medical, Inc. | Surgical stent |
USD654169S1 (en) | 2010-09-20 | 2012-02-14 | St. Jude Medical Inc. | Forked ends |
USD652927S1 (en) | 2010-09-20 | 2012-01-24 | St. Jude Medical, Inc. | Surgical stent |
USD653343S1 (en) | 2010-09-20 | 2012-01-31 | St. Jude Medical, Inc. | Surgical cuff |
USD652926S1 (en) | 2010-09-20 | 2012-01-24 | St. Jude Medical, Inc. | Forked end |
USD648854S1 (en) | 2010-09-20 | 2011-11-15 | St. Jude Medical, Inc. | Commissure points |
USD654170S1 (en) | 2010-09-20 | 2012-02-14 | St. Jude Medical, Inc. | Stent connections |
USD660432S1 (en) | 2010-09-20 | 2012-05-22 | St. Jude Medical, Inc. | Commissure point |
USD660967S1 (en) | 2010-09-20 | 2012-05-29 | St. Jude Medical, Inc. | Surgical stent |
US9579193B2 (en) * | 2010-09-23 | 2017-02-28 | Transmural Systems Llc | Methods and systems for delivering prostheses using rail techniques |
EP2618784B1 (en) * | 2010-09-23 | 2016-05-25 | Edwards Lifesciences CardiAQ LLC | Replacement heart valves and delivery devices |
PL3498225T3 (en) | 2010-10-05 | 2020-11-16 | Edwards Lifesciences Corporation | Prosthetic heart valve |
EP2629699B1 (en) | 2010-10-21 | 2017-01-04 | Medtronic, Inc. | Mitral bioprosthesis with low ventricular profile |
EP4119095A1 (en) * | 2011-03-21 | 2023-01-18 | Cephea Valve Technologies, Inc. | Disk-based valve apparatus |
US8945209B2 (en) | 2011-05-20 | 2015-02-03 | Edwards Lifesciences Corporation | Encapsulated heart valve |
US8840664B2 (en) * | 2011-06-15 | 2014-09-23 | Edwards Lifesciences Corporation | Heart valve prosthesis anchoring device and methods |
WO2012178115A2 (en) | 2011-06-24 | 2012-12-27 | Rosenbluth, Robert | Percutaneously implantable artificial heart valve system and associated methods and devices |
US8795357B2 (en) | 2011-07-15 | 2014-08-05 | Edwards Lifesciences Corporation | Perivalvular sealing for transcatheter heart valve |
US20140324164A1 (en) | 2011-08-05 | 2014-10-30 | Mitraltech Ltd. | Techniques for percutaneous mitral valve replacement and sealing |
WO2013021374A2 (en) * | 2011-08-05 | 2013-02-14 | Mitraltech Ltd. | Techniques for percutaneous mitral valve replacement and sealing |
EP2741711B1 (en) | 2011-08-11 | 2018-05-30 | Tendyne Holdings, Inc. | Improvements for prosthetic valves and related inventions |
US9358108B2 (en) * | 2011-09-12 | 2016-06-07 | Highlife Sas | Transcatheter valve prosthesis |
US9039757B2 (en) * | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
CA2892838A1 (en) | 2011-12-01 | 2013-06-06 | The Trustees Of The University Of Pennsylvania | Percutaneous valve replacement devices |
CA3095731C (en) | 2011-12-06 | 2023-02-07 | Aortic Innovations Llc | Device for endovascular aortic repair and method of using the same |
FR2985659B1 (en) * | 2012-01-13 | 2015-03-06 | Assist Publ Hopitaux De Paris | DEVICE FOR ANCHORING A PROTHETIC CARDIAC VALVE. |
US20130274873A1 (en) | 2012-03-22 | 2013-10-17 | Symetis Sa | Transcatheter Stent-Valves and Methods, Systems and Devices for Addressing Para-Valve Leakage |
WO2014022124A1 (en) * | 2012-07-28 | 2014-02-06 | Tendyne Holdings, Inc. | Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly |
US9023099B2 (en) | 2012-10-31 | 2015-05-05 | Medtronic Vascular Galway Limited | Prosthetic mitral valve and delivery method |
US10583002B2 (en) * | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
US20140350668A1 (en) | 2013-03-13 | 2014-11-27 | Symetis Sa | Prosthesis Seals and Methods for Sealing an Expandable Prosthesis |
FR3004336A1 (en) * | 2013-04-12 | 2014-10-17 | St George Medical Inc | MITRAL HEART VALVE PROSTHESIS AND RELIEF CATHETER |
US20140371844A1 (en) * | 2013-06-18 | 2014-12-18 | St. Jude Medical, Cardiology Division, Inc. | Transcatheter mitral valve and delivery system |
US9561103B2 (en) * | 2013-07-17 | 2017-02-07 | Cephea Valve Technologies, Inc. | System and method for cardiac valve repair and replacement |
US9839511B2 (en) * | 2013-10-05 | 2017-12-12 | Sino Medical Sciences Technology Inc. | Device and method for mitral valve regurgitation treatment |
US9072604B1 (en) * | 2014-02-11 | 2015-07-07 | Gilberto Melnick | Modular transcatheter heart valve and implantation method |
US9662203B2 (en) * | 2014-06-11 | 2017-05-30 | Medtronic Vascular, Inc. | Prosthetic valve with vortice-inducing baffle |
US10058424B2 (en) * | 2014-08-21 | 2018-08-28 | Edwards Lifesciences Corporation | Dual-flange prosthetic valve frame |
WO2016093877A1 (en) * | 2014-12-09 | 2016-06-16 | Cephea Valve Technologies, Inc. | Replacement cardiac valves and methods of use and manufacture |
US9962260B2 (en) * | 2015-03-24 | 2018-05-08 | St. Jude Medical, Cardiology Division, Inc. | Prosthetic mitral valve |
US10092400B2 (en) * | 2015-06-23 | 2018-10-09 | Edwards Lifesciences Cardiaq Llc | Systems and methods for anchoring and sealing a prosthetic heart valve |
US20170056176A1 (en) * | 2015-08-25 | 2017-03-02 | Edwards Lifesciences Corporation | Treatments for mitral valve insufficiency |
US20210298896A1 (en) * | 2016-03-08 | 2021-09-30 | Dura Llc | Prosthetic hemi heart valve |
WO2017156133A1 (en) * | 2016-03-08 | 2017-09-14 | Dura Biotech | Heart valve leaflet replacement system and method for same |
WO2018029680A1 (en) * | 2016-08-10 | 2018-02-15 | Mitraltech Ltd. | Prosthetic valve with concentric frames |
US10653510B2 (en) * | 2016-11-09 | 2020-05-19 | Boston Scientific Scimed, Inc. | Stent including displacement capabilities |
CA3051272C (en) * | 2017-01-23 | 2023-08-22 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
WO2018165064A1 (en) * | 2017-03-06 | 2018-09-13 | Boston Scientific Scimed, Inc. | Replacement heart valve system having docking station with sacrificial valve |
EP3372198B1 (en) * | 2017-03-06 | 2019-06-19 | AVVie GmbH | Implant for improving coaptation of an atrioventricular valve |
US10327895B2 (en) * | 2017-05-05 | 2019-06-25 | Vdyne, Llc | Pressure differential actuated prosthetic medical device |
US10973633B2 (en) * | 2017-05-14 | 2021-04-13 | Navigate Cardiac Structures, Inc. | Valved stent for orthotopic replacement of dysfunctional cardiac valve and delivery system |
US10729541B2 (en) * | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US11246704B2 (en) * | 2017-08-03 | 2022-02-15 | Cardiovalve Ltd. | Prosthetic heart valve |
US10888421B2 (en) * | 2017-09-19 | 2021-01-12 | Cardiovalve Ltd. | Prosthetic heart valve with pouch |
US20190038452A1 (en) * | 2017-08-07 | 2019-02-07 | Covidien Lp | Stent and associated methodologies for creating a stoma |
WO2019040781A1 (en) * | 2017-08-24 | 2019-02-28 | Medtronic Vascular, Inc. | Transseptal delivery systems having a deflecting segment and methods of use |
US20190175339A1 (en) * | 2017-12-12 | 2019-06-13 | Vdyne, Llc | Septomarginal trabecula attachment for heart valve repair |
EP3740144A1 (en) * | 2018-03-29 | 2020-11-25 | Boston Scientific Scimed Inc. | Systems and methods for performing endoscopic procedures |
US20210244557A1 (en) * | 2018-03-30 | 2021-08-12 | Metamodix, Inc. | Systems and method for stabilizing anti-migration anchor system |
US20210121290A1 (en) * | 2019-10-24 | 2021-04-29 | Abbott Laboratories | Sheet material for medical devices |
US20200391016A1 (en) * | 2019-06-17 | 2020-12-17 | NXT Biomedical | Method For Bypassing Defective Portions Of A Heart |
-
2015
- 2015-03-19 AU AU2015236516A patent/AU2015236516A1/en not_active Abandoned
- 2015-03-19 WO PCT/US2015/021367 patent/WO2015148241A1/en active Application Filing
- 2015-03-19 EP EP15715547.4A patent/EP3122289A1/en not_active Withdrawn
- 2015-03-19 JP JP2016558670A patent/JP6526043B2/en not_active Expired - Fee Related
- 2015-03-19 CR CR20160424A patent/CR20160424A/en unknown
- 2015-03-19 US US14/662,464 patent/US20150272737A1/en not_active Abandoned
- 2015-03-19 CA CA2941398A patent/CA2941398C/en not_active Expired - Fee Related
-
2019
- 2019-04-23 US US16/391,414 patent/US11246706B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090292350A1 (en) * | 2008-01-24 | 2009-11-26 | Medtronic, Inc. | Stents for Prosthetic Heart Valves |
US20090216310A1 (en) * | 2008-02-26 | 2009-08-27 | Helmut Straubinger | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US20110208290A1 (en) * | 2008-02-26 | 2011-08-25 | Helmut Straubinger | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US20100082094A1 (en) * | 2008-09-29 | 2010-04-01 | Arshad Quadri | Heart valve |
US20100298931A1 (en) * | 2009-04-15 | 2010-11-25 | Arshad Quadri | Vascular implant and delivery system |
US20120271398A1 (en) * | 2009-11-02 | 2012-10-25 | Symetis Sa | Aortic bioprosthesis and systems for delivery thereof |
US20140277411A1 (en) * | 2011-09-12 | 2014-09-18 | Highlife Sas | Transcatheter valve prosthesis |
US20140343669A1 (en) * | 2013-04-04 | 2014-11-20 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
Cited By (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9974669B2 (en) | 2005-11-10 | 2018-05-22 | Edwards Lifesciences Cardiaq Llc | Percutaneous heart valve |
US10456277B2 (en) | 2005-11-10 | 2019-10-29 | Edwards Lifesciences Cardiaq Llc | Percutaneous heart valve |
US20210196457A1 (en) * | 2008-05-01 | 2021-07-01 | Edwards Lifesciences Corporation | Prosthetic heart valve assembly |
US11717401B2 (en) * | 2008-05-01 | 2023-08-08 | Edwards Lifesciences Corporation | Prosthetic heart valve assembly |
US10952846B2 (en) * | 2008-05-01 | 2021-03-23 | Edwards Lifesciences Corporation | Method of replacing mitral valve |
US10149756B2 (en) | 2008-09-29 | 2018-12-11 | Edwards Lifesciences Cardiaq Llc | Heart valve |
US11819404B2 (en) | 2008-09-29 | 2023-11-21 | Edwards Lifesciences Cardiaq Llc | Heart valve |
US11589983B2 (en) | 2008-09-29 | 2023-02-28 | Edwards Lifesciences Cardiaq Llc | Heart valve |
US10646334B2 (en) | 2008-09-29 | 2020-05-12 | Edwards Lifesciences Cardiaq Llc | Heart valve |
US10441412B2 (en) | 2009-04-15 | 2019-10-15 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US11376119B2 (en) | 2009-04-15 | 2022-07-05 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US10524901B2 (en) | 2009-09-29 | 2020-01-07 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve |
US10959840B2 (en) * | 2010-01-20 | 2021-03-30 | Micro Interventional Devices, Inc. | Systems and methods for affixing a prosthesis to tissue |
US20160095704A1 (en) * | 2010-01-20 | 2016-04-07 | Micro Interventional Devices, Inc. | Systems and Methods for Affixing A Prosthetic to Tissue |
US11452597B2 (en) | 2010-06-21 | 2022-09-27 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve |
US10639146B2 (en) | 2010-06-21 | 2020-05-05 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve |
US10485660B2 (en) | 2010-06-21 | 2019-11-26 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve |
US10517725B2 (en) | 2010-12-23 | 2019-12-31 | Twelve, Inc. | System for mitral valve repair and replacement |
US11571303B2 (en) | 2010-12-23 | 2023-02-07 | Twelve, Inc. | System for mitral valve repair and replacement |
US9421098B2 (en) | 2010-12-23 | 2016-08-23 | Twelve, Inc. | System for mitral valve repair and replacement |
US20190336287A1 (en) * | 2011-03-21 | 2019-11-07 | Cephea Valve Technologies, Inc. | Disk-based Valve Apparatus And Method For The Treatment Of Valve Dysfunction |
US11931252B2 (en) * | 2011-03-21 | 2024-03-19 | Cephea Valve Technologies, Inc. | Disk-based valve apparatus and method for the treatment of valve dysfunction |
US10028827B2 (en) | 2011-06-21 | 2018-07-24 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US9572662B2 (en) | 2011-06-21 | 2017-02-21 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US9579196B2 (en) | 2011-06-21 | 2017-02-28 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US9585751B2 (en) | 2011-06-21 | 2017-03-07 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10034750B2 (en) | 2011-06-21 | 2018-07-31 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10751173B2 (en) | 2011-06-21 | 2020-08-25 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US11712334B2 (en) | 2011-06-21 | 2023-08-01 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US11523900B2 (en) | 2011-06-21 | 2022-12-13 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US11617648B2 (en) | 2011-10-19 | 2023-04-04 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US10945835B2 (en) | 2011-10-19 | 2021-03-16 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US10299917B2 (en) | 2011-10-19 | 2019-05-28 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US10299927B2 (en) | 2011-10-19 | 2019-05-28 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US10702380B2 (en) | 2011-10-19 | 2020-07-07 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
US10335278B2 (en) | 2011-10-19 | 2019-07-02 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US11628063B2 (en) | 2011-10-19 | 2023-04-18 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9295552B2 (en) | 2011-10-19 | 2016-03-29 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US11497603B2 (en) | 2011-10-19 | 2022-11-15 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9901443B2 (en) | 2011-10-19 | 2018-02-27 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US10016271B2 (en) | 2011-10-19 | 2018-07-10 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
US11826249B2 (en) | 2011-10-19 | 2023-11-28 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
US11197758B2 (en) | 2011-10-19 | 2021-12-14 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US10052204B2 (en) | 2011-10-19 | 2018-08-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US11129714B2 (en) | 2012-03-01 | 2021-09-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
US11324591B2 (en) | 2013-03-14 | 2022-05-10 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US10583000B2 (en) | 2013-03-14 | 2020-03-10 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US10716664B2 (en) | 2013-03-14 | 2020-07-21 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US11234821B2 (en) | 2013-05-20 | 2022-02-01 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
US10111747B2 (en) | 2013-05-20 | 2018-10-30 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
US10004599B2 (en) | 2014-02-21 | 2018-06-26 | Edwards Lifesciences Cardiaq Llc | Prosthesis, delivery device and methods of use |
US10952849B2 (en) | 2014-02-21 | 2021-03-23 | Edwards Lifesciences Cardiaq Llc | Prosthesis, delivery device and methods of use |
US11633279B2 (en) | 2014-02-21 | 2023-04-25 | Edwards Lifesciences Cardiaq Llc | Prosthesis, delivery device and methods of use |
US10179044B2 (en) | 2014-05-19 | 2019-01-15 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve |
US11045313B2 (en) | 2014-05-19 | 2021-06-29 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve |
US10010414B2 (en) | 2014-06-06 | 2018-07-03 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US10687939B2 (en) | 2014-06-06 | 2020-06-23 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US11684471B2 (en) | 2014-06-06 | 2023-06-27 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a native mitral or tricuspid valve |
US11850147B2 (en) | 2015-04-21 | 2023-12-26 | Edwards Lifesciences Corporation | Percutaneous mitral valve replacement device |
US10441416B2 (en) | 2015-04-21 | 2019-10-15 | Edwards Lifesciences Corporation | Percutaneous mitral valve replacement device |
US10376363B2 (en) | 2015-04-30 | 2019-08-13 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve, delivery system for replacement mitral valve and methods of use |
US11389292B2 (en) | 2015-04-30 | 2022-07-19 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve, delivery system for replacement mitral valve and methods of use |
US11617646B2 (en) | 2015-05-14 | 2023-04-04 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
US10226335B2 (en) | 2015-06-22 | 2019-03-12 | Edwards Lifesciences Cardiaq Llc | Actively controllable heart valve implant and method of controlling same |
US11083576B2 (en) | 2015-06-22 | 2021-08-10 | Edwards Lifesciences Cardiaq Llc | Actively controllable heart valve implant and method of controlling same |
US10092400B2 (en) | 2015-06-23 | 2018-10-09 | Edwards Lifesciences Cardiaq Llc | Systems and methods for anchoring and sealing a prosthetic heart valve |
US10842620B2 (en) | 2015-06-23 | 2020-11-24 | Edwards Lifesciences Cardiaq Llc | Systems and methods for anchoring and sealing a prosthetic heart valve |
US11844690B2 (en) | 2015-06-23 | 2023-12-19 | Edwards Lifesciences Cardiaq Llc | Systems and methods for anchoring and sealing a prosthetic heart valve |
US10820996B2 (en) | 2015-08-21 | 2020-11-03 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
US10238490B2 (en) | 2015-08-21 | 2019-03-26 | Twelve, Inc. | Implant heart valve devices, mitral valve repair devices and associated systems and methods |
US11576782B2 (en) | 2015-08-21 | 2023-02-14 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
US10117744B2 (en) | 2015-08-26 | 2018-11-06 | Edwards Lifesciences Cardiaq Llc | Replacement heart valves and methods of delivery |
US11278405B2 (en) | 2015-08-26 | 2022-03-22 | Edwards Lifesciences Cardiaq Llc | Delivery device and methods of use for transapical delivery of replacement valve |
US10575951B2 (en) | 2015-08-26 | 2020-03-03 | Edwards Lifesciences Cardiaq Llc | Delivery device and methods of use for transapical delivery of replacement mitral valve |
US10758345B2 (en) | 2015-08-26 | 2020-09-01 | Edwards Lifesciences Cardiaq Llc | Replacement heart valves and methods of delivery |
US10350066B2 (en) | 2015-08-28 | 2019-07-16 | Edwards Lifesciences Cardiaq Llc | Steerable delivery system for replacement mitral valve and methods of use |
US11253364B2 (en) | 2015-08-28 | 2022-02-22 | Edwards Lifesciences Cardiaq Llc | Steerable delivery system for replacement mitral valve and methods of use |
US11833034B2 (en) | 2016-01-13 | 2023-12-05 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
CN108495602A (en) * | 2016-01-27 | 2018-09-04 | 美敦力公司 | System for repositioning the valve assemblies disposed completely |
US11717398B2 (en) | 2016-02-05 | 2023-08-08 | Edwards Lifesciences Corporation | Methods for docking a heart valve |
JP7383516B2 (en) | 2016-02-05 | 2023-11-20 | エドワーズ ライフサイエンシーズ コーポレイション | Heart valve docking devices and systems |
US11717399B2 (en) | 2016-02-05 | 2023-08-08 | Edwards Lifesciences Corporation | Devices and systems for docking a heart valve |
US11819403B2 (en) | 2016-02-05 | 2023-11-21 | Edwards Lifesciences Corporation | Devices and systems for docking a heart valve |
US11596514B2 (en) | 2016-02-05 | 2023-03-07 | Edwards Lifesciences Corporation | Devices and systems for docking a heart valve |
US11938314B2 (en) | 2016-02-22 | 2024-03-26 | The Charles Stark Draper Laboratory, Inc. | Method of manufacturing an implantable neural electrode interface platform |
USD815744S1 (en) | 2016-04-28 | 2018-04-17 | Edwards Lifesciences Cardiaq Llc | Valve frame for a delivery system |
US11033390B2 (en) | 2016-04-29 | 2021-06-15 | Medtronic Vascular, Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
US10265172B2 (en) | 2016-04-29 | 2019-04-23 | Medtronic Vascular, Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
US10321994B2 (en) | 2016-05-13 | 2019-06-18 | St. Jude Medical, Cardiology Division, Inc. | Heart valve with stent having varying cell densities |
EP3454785B1 (en) | 2016-05-13 | 2021-11-17 | St. Jude Medical, Cardiology Division, Inc. | Heart valve with stent having varying cell densities |
WO2017196912A1 (en) * | 2016-05-13 | 2017-11-16 | St. Jude Medical, Cardiology Division, Inc. | Heart valve with stent having varying cell densities |
US10350062B2 (en) * | 2016-07-21 | 2019-07-16 | Edwards Lifesciences Corporation | Replacement heart valve prosthesis |
US11224507B2 (en) | 2016-07-21 | 2022-01-18 | Edwards Lifesciences Corporation | Replacement heart valve prosthesis |
US20180021129A1 (en) * | 2016-07-21 | 2018-01-25 | Edwards Lifesciences Corporation | Replacement heart valve prosthesis |
US11931258B2 (en) | 2016-08-19 | 2024-03-19 | Edwards Lifesciences Corporation | Steerable delivery system for replacement mitral valve and methods of use |
US10646340B2 (en) | 2016-08-19 | 2020-05-12 | Edwards Lifesciences Corporation | Steerable delivery system for replacement mitral valve |
US11504229B2 (en) | 2016-08-26 | 2022-11-22 | Edwards Lifesciences Corporation | Multi-portion replacement heart valve prosthesis |
US10639143B2 (en) | 2016-08-26 | 2020-05-05 | Edwards Lifesciences Corporation | Multi-portion replacement heart valve prosthesis |
US10052201B2 (en) | 2016-09-21 | 2018-08-21 | Peijia Medical Co., Ltd. | Valved stent for mitral and tricuspid heart valve replacement |
US11241307B2 (en) | 2016-10-13 | 2022-02-08 | Boston Scientific Scimed, Inc. | Replacement heart valve with diaphragm |
US10758348B2 (en) | 2016-11-02 | 2020-09-01 | Edwards Lifesciences Corporation | Supra and sub-annular mitral valve delivery system |
US11510778B2 (en) | 2016-11-02 | 2022-11-29 | Edwards Lifesciences Corporation | Supra and sub-annular mitral valve delivery system |
US11633278B2 (en) | 2017-01-23 | 2023-04-25 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
US20180206985A1 (en) * | 2017-01-23 | 2018-07-26 | Spencer NOE | Replacement mitral valves |
US10828153B2 (en) * | 2017-01-23 | 2020-11-10 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
US11090158B2 (en) | 2017-01-23 | 2021-08-17 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
EP3570779B1 (en) | 2017-01-23 | 2023-02-15 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
USD977101S1 (en) | 2017-02-01 | 2023-01-31 | Edwards Lifesciences Corporation | Stent |
US11389295B2 (en) | 2017-04-18 | 2022-07-19 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
US11654021B2 (en) | 2017-04-18 | 2023-05-23 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
US11737873B2 (en) | 2017-04-18 | 2023-08-29 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
US11786370B2 (en) | 2017-05-11 | 2023-10-17 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
US11559398B2 (en) | 2017-06-02 | 2023-01-24 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
US11464659B2 (en) | 2017-06-06 | 2022-10-11 | Twelve, Inc. | Crimping device for loading stents and prosthetic heart valves |
US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
US11877926B2 (en) | 2017-07-06 | 2024-01-23 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10813757B2 (en) | 2017-07-06 | 2020-10-27 | Edwards Lifesciences Corporation | Steerable rail delivery system |
US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US11883287B2 (en) | 2017-07-06 | 2024-01-30 | Edwards Lifesciences Corporation | Steerable rail delivery system |
US11123186B2 (en) | 2017-07-06 | 2021-09-21 | Edwards Lifesciences Corporation | Steerable delivery system and components |
US11666444B2 (en) | 2017-08-03 | 2023-06-06 | The Regents Of The University Of California | Atrial cage for placement, securing and anchoring of atrioventricular valves |
WO2019028264A1 (en) * | 2017-08-03 | 2019-02-07 | The Regents Of The University Of California | Atrial cage for placement, securing and anchoring of atrioventricular valves |
US11684474B2 (en) | 2018-01-25 | 2023-06-27 | Edwards Lifesciences Corporation | Delivery system for aided replacement valve recapture and repositioning post-deployment |
US11051934B2 (en) | 2018-02-28 | 2021-07-06 | Edwards Lifesciences Corporation | Prosthetic mitral valve with improved anchors and seal |
US11672657B2 (en) | 2018-10-05 | 2023-06-13 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
US10912644B2 (en) | 2018-10-05 | 2021-02-09 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
WO2020167827A1 (en) * | 2019-02-11 | 2020-08-20 | W. L. Gore & Associates, Inc. | Universal heart valve device |
CN113423364A (en) * | 2019-02-11 | 2021-09-21 | W.L.戈尔及同仁股份有限公司 | Universal heart valve device |
US11471282B2 (en) | 2019-03-19 | 2022-10-18 | Shifamed Holdings, Llc | Prosthetic cardiac valve devices, systems, and methods |
US20210236276A1 (en) * | 2020-01-31 | 2021-08-05 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
US11931253B2 (en) * | 2020-01-31 | 2024-03-19 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
US11951001B2 (en) | 2020-07-08 | 2024-04-09 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grapsing intralumenal tissue and methods of delivery |
WO2022156335A1 (en) * | 2021-01-20 | 2022-07-28 | 上海纽脉医疗科技股份有限公司 | Interventional artificial heart valve and medical apparatus |
US20220265421A1 (en) * | 2021-02-19 | 2022-08-25 | Johnson Consulting Llc | Anchoring frame device for an artificial valve and related systems and method |
Also Published As
Publication number | Publication date |
---|---|
JP6526043B2 (en) | 2019-06-05 |
WO2015148241A1 (en) | 2015-10-01 |
US20190247189A1 (en) | 2019-08-15 |
CR20160424A (en) | 2016-12-08 |
US11246706B2 (en) | 2022-02-15 |
AU2015236516A1 (en) | 2016-09-22 |
CA2941398A1 (en) | 2015-10-01 |
JP2017508555A (en) | 2017-03-30 |
CA2941398C (en) | 2018-05-01 |
EP3122289A1 (en) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11246706B2 (en) | Transcatheter mitral valve stent frames | |
US11311375B2 (en) | Stents with anchoring sections | |
US10856974B2 (en) | Heart valve repair and replacement | |
US10433957B2 (en) | Stent cell bridge for cuff attachment | |
US10743992B2 (en) | Prosthetic mitral valve | |
US11278396B2 (en) | Transcatheter mitral valve design | |
US20190183639A1 (en) | Transcatheter Mitral Valve: Off-Center Valve Design | |
US20180353291A1 (en) | Mitral Valve Replacement Toggle Cell Securement | |
US20170165053A1 (en) | Bowed Runners for Paravalvular Leak Protection | |
EP3909548B1 (en) | Transcatheter mitral valve fixation concepts | |
US11471277B2 (en) | Prosthetic tricuspid valve replacement design | |
WO2015179468A1 (en) | Self-expanding heart valves for coronary perfusion and sealing | |
US20230025890A1 (en) | Transcatheter Valve To Treat Small Native Mitral Anatomy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ST. JUDE MEDICAL, CARDIOLOGY DIVISION, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DALE, THEODORE P;PARA, ANDREA N;SATAM, GAURAV;AND OTHERS;SIGNING DATES FROM 20140408 TO 20140415;REEL/FRAME:064981/0641 |